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Summary 
 
The incidence of breast cancer has increased sharply among women in the last 3 decades 
in Singapore. The aim of the present thesis is to investigate various aspects of breast 
cancer in Singapore, using epidemiology and experimental studies. We investigated the 
epidemiology of ethnic variation (Chinese, Malay and Indian) in breast cancer in 
Singapore women. In addition, we carried out preliminary studies on leptin, which is 
related to body mass index, on a breast cancer cell line in vitro.  
 
To study the epidemiology of ethnic variation in breast cancer, the number of cases and 
incidence rates of breast cancer from 1968 to 1998 were obtained from the Singapore 
Cancer Registry Report. In addition, a case-control study was designed and the results 
were analysed by logistic regression. Bivariate odds ratios (OR) for risk of breast cancer 
and 95% confidence intervals (95% CI) were calculated for ethnic status. Our study 
showed that although the three main ethnic groups have had striking increases in 
incidence of breast cancer over the past three decades, the pattern of increase was 
different. The greatest incidence rate was in the Chinese group while the highest annual 
increase was in the Malay group. The Indian group had the highest post-menopausal 
breast cancer incidence while Chinese group had the highest incidence in pre-menopausal 
breast cancer. The case-control study showed that while Chinese, Malay and Indian 
women shared some common risk factors for breast cancer, other factors related to breast 
cancer were distinguishable between the three ethnic groups. Cycle length of menses 
period, menopause status, age at first marriage, number of full term pregnancies, age at 
first pregnancy and oral contraceptive use were in this subset of distinguishable factors 
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related to breast cancer risk among Chinese, Malay and Indian women in Singapore. 
These factors may help to provide an explanation for different ethnic patterns for 
incidence rates of breast cancer.  
 
In the experimental studies (Part II of this thesis), the results demonstrated that the role of 
leptin on mammary carcinoma cell line (MCF-7) proliferation was mediated by the 
specific leptin receptor in vitro. We found that the leptin receptor is expressed on the 
MCF-7 breast cancer cell line and it is activated by leptin via the Mitogen-activated 
protein kinase (MAP-kinase) pathway. Reverse transcription-polymerase chain reaction 
(RT-PCR) study demonstrated the existence of leptin receptor mRNA in MCF-7 cell line. 
Double labeling cofocal Laser scanning microscopy also confirmed the existence of leptin 
receptor in the same cell line. Western blot demonstrated the leptin receptor protein 
expression in MCF-7 cells. Further, P44/42 MAP Kinase activity was increased by 
100ng/ml human recombinant leptin in a dose and time dependent manner. Cell 
proliferation, assessed with 5-bromo-2-deoxyuridine (BrdU) uptake into MCF-7 cells, was 
also significantly increased by the incubation of 100ng/ml leptin for 24hours, compared 
with samples which had no leptin, or had addition of specific inhibitor of P44/42 MAP 
Kinase, Mek ½ inhibitor (U0126). Finally, cDNA microarray was used to investigate 
other lept in effects on the MCF-7 breast cancer cell line. In conclusion, the leptin receptor 
exists in the MCF-7 human breast cancer cell and through its specific leptin receptor, 
leptin has the ability to stimulate breast cancer cell proliferation in vitro. 
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Chapter 1 Introduction 
 
1.1 Breast cancer in Singapore 
 
The incidence of breast cancer in Asian countries has increased sharply over the past three 
decades. In Singapore, the number of women diagnosed with breast cancer has increased 
at a mean rate of 3.5 % annually since 1968. Breast carcinoma is currently the most 
common female cancer, accounting for 3574 new cases during 1993-1997. Up to 20% of 
all cancers diagnosed in Singapore women is breast cancer. The age-standardized rate 
doubled from 20 (1970) to 40 (1990) (per 100,000 per year) and has been extrapolated to 
reach 55 (per 100,000 per year) by the year 2000.  
 
In the last 30 years, Singapore has transited from a developing to a newly industrialized 
economy country and accompanying this change, Singaporeans also have experienced 
great changes in lifestyle, environment, and patterns of disease. The rise in breast cancer 
incidence, and the possibility of ethnic variation in this rise, has not been studied 
previously. Although genetic causes play an important role in breast cancer, the rapidity of 
the change in incidence suggests that environment changes, lifestyle changes, may be the 
important or even dominant factors. 
 
1.2 Ethnic variation of breast cancer in Singapore 
 
 The incidence of female breast cancer varies markedly between countries and ethnic 
groups. The highest incidence rates are in the United States and Northern Europe, 
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intermediate in Southern and Eastern Europe, and lower in Asia and the Far East. In 
Singapore, which comprises of three main ethnic groups, there may be differences in 
ethnic incidence rates for breast cancer. 
 
Different lifestyles exist in the three main ethnic groups in Singapore women. It is now 
widely accepted that life-style related factors such as, reproductive and body mass index 
are associated with risk of breast cancer. These factors maybe partially explain the ethnic 
variation in the risk of breast cancer. 
 
1.3 Aims of the present study 
 
Singapore is a multi-ethnic country. In the 1990 census the total population was 
3,016,379, comprising 77.7% Chinese, 14.1% Malays, 7.1% Indians and 1.1% others 
[Lau, 1992]. 
 
We noted a trend in the breast cancer incidence among Singapore women from 1968 to 
1997 had uneven increase among the different major ethnic groups. In this thesis, the aim 
will be to update the analysis of the overall breast cancer trend in Singapore following a 
primary study “Trends in incidence 1968-1992” [Seow A et al, 1996]) and in particular, 
describe the differences of incidence rates of breast cancer among the three ethnic groups.  
 
We also aimed to determine the risk factors for breast cancer in Singapore women by 
carrying out a pilot case-control study. We hypothesize that women with breast cancer 
would have a higher proportion of identified risk factors compared with the control 
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women. We aimed to compare the established risk factors of breast cancer among 
different ethnic groups in our subjects. Specifically, we aimed to examine the role of some 
hormone related risk factors in variation incidence rates among different ethnic groups.  
 
Finally, in this thesis, we were also interested to examine the role of leptin, a hormone that 
is closely associated with the body mass index, to investigate its involvement in the 
metabolic pathways of human breast caner cell. This is described in Part II of this thesis. 
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Chapter 2 Literature Review 
 
The incidence of breast cancer has been steadily rising since formal registration of this 
tumor began in the 1930s. From 1940-1982, the age-standardized incidence rate has risen 
by an average of 1.2% per year in Connecticut of US, the state with the longest continuous 
cancer registration [Miller, et al, 1991]. In both industrialized and developing countries, 
similar long-term increases are being observed [Boyle, et al., 1990; Prentice, et al. 1990].  
 
In Singapore, the breast cancer incidence rate rose from 134 per 100,000 in 1970 to 715 
per 100,000 in 1995 [Chia, et al, 1996& 2000]. This increase has occur red in both younger 
and elder women. Some of the recent increase in breast cancer incidence rather than 
mortality is likely to be partly the result of diagnosis of breast cancer at progressively 
earlier stages and, hence, higher 5-year survival rates. But the most important reason of 
sharply increasing rate may be still due to the risk factors of breast cancer induced by 
factors in the modern lifestyle.  
 
Risk factors for breast cancer have been extensively investigated. Most of the population-
based studies have been done in Europe and other Western countries, which suggest that 
hormonal-related factors variation induced by modern lifestyle, such as reproductive 
factors, body mass index, predispose specific populations to higher risk.  
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In this section, risk factors of breast cancer, hypotheses for the relationship of hormonal 
related factors and variation of breast cancer incidence rates are reviewed. In addition, as 
Singapore is a multi-ethnic country, and as this thesis will investigate ethnic variation in 
breast cancer, previous research related to hormonal risk factors and ethnicity will also be 
reviewed. 
 
2.1 Risk factors of breast cancer 
 
Despite the large number of risk factors, few are strongly associated with the development 
of breast cancer, and no single factor or combination of factors can predict the occurrence 
of breast cancer in any one individual. Through numerous epidemiological studies, an 
array of breast cancer risk factors has been established (Table2.1.1). 
 
The risks associated with reproductive variables of never having children, being of a late 
age at first birth, having an early menarche, having a late menopause, are thought to be 
related to the hormonal environment to which the breast is exposed (during pregnancy or 
during a long menstrual history). The high body mass index is thought to be helpful to 
decrease the risk of breast cancer in premenopausal women, whereas it is a risk factor for 
postmenopausal women [Ng, et al, 1997; Le, et al 1988]. 
 
Several other breast cancer risk factors have been examined, but the results across studies 
are inconsistent. These include use of exogenous hormones, notably oral contraceptives 
and estrogens replacements during menopause. 
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Although there are only a few well-designed studies, most that are published have shown 
decreased risks of breast cancer among women who are more physically active with 
regular exercise. There is also limited evidence of an increased breast cancer risk among 
women who smoke or have the genetic predisposition to be slow acetylators of aromatic 
amines. Passive exposure to environmental tobacco smoke may also be a risk factor of 
breast cancer [Adlercreutz et al, 1990].  
 
Table 2.1.1 Factors  that influence breast cancer risk 
Established Positive Risk Factor 
 
Established Negative Risk Factor 
 
1. Increasing age 1.Early bilateral oophorectomy 
2. Early menarche 2.Premenopausal obesity 
3. Late menopause  
4. Proliferative breast disease  
5. Family history of breast cancer  
6. Postmenopausal obesity  
7. Late first term pregnancy or nulliparity  
8. BRCA1 or BRCA2 mutations  
Possible Positive Risk Factors Possible Negative Risk Factors 
1. Postmenopausal estrogen replacement     
therapy 
2. Oral contraceptive, long-term use at 
young age 
1. Breast feeding 
2. Physical activity (exercise) 
3. Irregular menses, with long interval   
between menses 
 
Source: Darcy et al. 1998 
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2.1.1 Endogenous Hormonal Factors 
 
2.1.1.1 Endogenous Estrogen  
 
Estrogens stimulate division of the breast epithelial cells, and increased cell division 
increases the chance of mutation occurring. It therefore has been hypothesized that breast 
cancer risk increases with increasing concentrations of estradiol in the serum. Several 
comparisons of estrogen levels between low and high risk ethnic groups [Dickinson et al, 
1974; Glodin et al, 1986; Key et al, 1990; Shimizu et al, 1990], but not all [Trichopoulos 
et al 1984, Goodman et al, 1988], support the idea that populations with low breast cancer 
risk have lower levels of endogenous estrogens than women in high risk populations.  
 
In addition to levels of endogenous estrogens, variations in estrogen metabolism have 
been investigated [Kabat GC et al; 1997, Ursin G. et al, 1999]. Estradiol is metabolized in 
two main competing pathways, via 16a-hydroxylation and 2-hydoxylation, and probably 
also via a minor 4-hydroxylation [Nebert DW, 1993; Yager JD et al. 1996]. It has been 
proposed [Yager JD et al. 1996; Bradlow HL, et al, 1995] that women who metabolize a 
larger proportion of their endogenous estrogen via 16a -hydroxylation are at greater risk. 
The reason is that 16a-hydroxylation has genotoxic effects, damages DNA, and enhances 
breast cell growth, whereas 2-hydroxyestrone inhibits breast cell proliferation although 2-
hydroxy compounds also appear to have some estrogenic and growth promoting effects 
[Yager JD et al. 1996]. A study from Singapore [Ho GH, et al, 1998] also detected a 
highly protective effect of the 2-hydroxyestrone to 16a -hydroxyestrone ratio. 
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2.1.1.2 Endogenous hormone related factors  
 
Although studies on endogenous estrogens are still inconclusive, the circumstantial 
evidence that estrogens contribute to breast cancer risk is strong.  
 
 Numerous studies have shown significant association of breast cancer with the age at 
menarche, menopause, and first pregnancy. Based on the statistics from NIH (National 
Cancer Institute of USA) cancer registry [Ries et al. 1994], the absolute age-specific 
incidence of breast cancer is higher in postmenopausal than premenopausal women, while 
the rate of  the rise of the curve reaches the highest point to the time of menopause, then 
slows down to one-sixth in the premenopausal period. This has led to the suggestion that 
ovarian activity plays a major part in the causation of breast cancer [Henderson et al.  
1988]. An increased number of ovulatory cycles has been suggested to be the common 
mechanism of increased risk. 
 
Several researchers [Madigan, et al 1995; Rockhill, et al 1998; Bruzzi, et al 1985; 
Seidman, et al 1982] have developed models to estimate the attributable breast cancer risk 
due to menstrual and reproductive risk factors, resulting in estimates between 21% and 
55%. A comparison between breast cancer risk factors in China and in the United States 
[Smith-Warner, et al 1998] found that the combined population attributable risk was 44% 
for reproductive factors, 32% for anthropometric factors, and 63% for all factors 
combined. 
 
Between 1994 and 1996, a prospective case-control study [Ng, et al, 1997] was conducted 
among Chinese women in Singapore to investigate for factors associated with the risk of 
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breast carcinoma ages 45 to 69 years. Reproductive and menstrual factors significantly 
related to risk for breast carcinoma were number of deliveries (OR=0.81; 95%CI, 0.7-0.9; 
P<0.001), age at last delivery (P=0.03), and use of hormone replacement therapy (OR: 
0.54; 95% C.I, 0.3~0.9; P<0.01). 
 
Known breast cancer risk factors [Henderson, et al 1982] can be understood as measures 
of the cumulative exposure of the breast to estrogen and, perhaps progesterone , as a result 
of the frequency of ovulatory menstrual cycles. Therefore, both a late menarche and an 
early menopause decrease risk, probably by reducing lifetime exposure to these ovarian 
hormones. 
 
Studies of the effect of lactation on breast cancer risk have also been inconclusive [Layde 
PM, et al, 1989; Kvale G and Heuch I, 1988]; but recent studies have suggested that a 
long duration of lactation reduces breast cancer risk in premenopausal women [Newcomb 
PA, et al, 1994].  
 
In 1981, Pike et al published their notable work showing that young women (under age 
32) who had experienced an abortion before their first live birth had a 140% increased risk 
of breast cancer. A number of studies followed but finally in 1994, Daling et al published 
a large study, which noted that women who had an abortion before first birth suffered a 
40% increased risk, and that this increased to 150% if the abortion was before age 18. 
Finally, in 1996, in what is openly regarded as the most meticulously comprehensive 
meta-analysis of all the abortion/breast cancer research studies ever done, Brind et al, 
[1996] found that women who had an abortion before their first term child had a 50% 
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increased of developing breast cancer while women who had an abortion after their first 
child sus tained a 30% increased risk. This has not been completely accepted, and some 
studies [Davidson, 2001; Sanderson, et al. 2001] do not show any significant association. 
 
As we all know, when a woman becomes pregnant, a number of hormone levels increase 
dramatically in her body. Three especially notable ones are estradiol, progesterone (i.e., 
the female sexual hormones), and B-hCG (Beta-human Chorionic Gonadotropin). All of 
these hormones, especially the last, serve to stimulate immature breast cells to mature into 
fully differentiated cells [Russo J and Russo IH, 1994]. If this process gets artificially 
interrupted, by way of an induced abortion, the hormone levels drop dramatically thereby 
suspending the natural process of maturation of many of the woman's breast cells. This is 
referred to as a "hormonal blow" by researchers. These cells are now "vulnerable" to 
carcinogens since they were left "in limbo": that is, they started the maturation process, 
but were never able to complete it. Cells that have fully matured are less vulnerable to 
mutagenic carcinogens than cells that are in the process of maturation. 
 
2.1.2 Exogenous Hormonal Factors 
 
Oral contraceptive (OC) use and its possible relation to breast carcinoma risk have 
generated debate for the last several decades. The literature was reviewed in detail by 
Spicer and Pike, with women stratified by menopausal status at the time of diagnosis of 
breast carcinoma [Spicer, et al 1994]. They studied 5 population-based case-control 
studies and 3 cohort studies of women younger than 45 years old. All 8 studies 
demonstrated an increased risk of breast carcinoma in OC users. In contrast, the 3 
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population-based case-control studies and 2 cohort studies of women diagnosed with 
breast carcinoma after age 45 years showed no effect with OC use. The magnitude of the 
increase in risk for premenopausal women at diagnosis was estimated to 3.1% per year of 
OC use [Spicer, et al 1994].  
 
Other studies have examined the use of OCs in African American populations. Mayberry 
demonstrated an increased risk with OC use for black women ages 20-39 years, but such 
an increase in risk with OC use was not observed for the group ages 40-54 years 
[Mayberry, et al 1994]. Similar effects of OC use were observed by Palmer et al [Palmer, 
et al 1995]. Among black women younger than 45 years, 3 or more years of OC use was 
associated with increased risk of 2.8 (95% CI, 1.5-2.0), with no association observed for 
women ages 45-59 year. Brinton et al (1997) observed a reversed pattern for the effect of 
OC use by age at diagnosis. In that study a stronger risk with the duration of OC use was 
observed for black women ages 40-54 years. Overall, the epidemiological studies seem to 
indicate an increase in risk of breast carcinoma with OC use in premenopausal but not  
postmenopausal white women, with less consistent results for black women. This ethnic 
variation within U.S.A has not been emphasized much and may be relevant to the findings 
in Singapore presented in this thesis. 
 
OCs contain many of the same hormones as HRT, albeit in different doses and ratios. By 
analogy, then, since exogenous estrogen-progestin combinations may be associated with 
breast carcinoma in premenopausal women, the same may be true for postmenopausal 
women taking estrogen replacement therapy with or without progestin. 
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In addition, estrogen replacement therapy could not account for the difference in breast 
cancer risk between Japanese and Caucasian women in a study in Hawaii [Nomura, et al, 
1986]. The possible importance of bio-available estradiol fractions determined by sex 
hormone-binding globulin, the proportion of free estradiol, and progesterone has been 
suggested as a factor for the differences [Henderson, et al 1982; Pike, et al 1993].  
 
2.1.3  Anthropometrics 
 
In studies of breast cancer, anthropometric measurements may serve as useful biologic 
markers of environmental factors, including contemporary and past diets. The importance 
of body weight and body mass index (BMI) as risk factors among women has been well 
documented [Eugenia E, et al, 2003; Ng, et al, 1997; Le, et al 1988]. 
 
A case-control study from Hawaii [Le, et al 1988] described a protective effect of 
adolescent body mass against premenopausal breast cancer and an association between 
adult weight and postmenopausal breast cancer risk. Among women with Asian ancestries 
in the United States [Zidgler, et al 1996], adiposity conferred twice the breast cancer risk 
and recent weight gain of more than ten pounds tripled the risk, a stronger effect than 
usually found among Caucasian women [Hunter, et al 1993]. Despite the low levels of 
BMI in Japan, BMI [Hu, et al 1997] and weight gain [Hirose, et al, 1999] were confirmed 
as predictors of postmenopausal breast cancer risk.  
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Another two studies of anthropometrics have been conducted in Asian countries. A breast 
carcinoma case-control study in Singapore Chinese women ages 45-69 years (n=204 cases 
and 882 controls) found that although obesity did not predict risk for breast carcinoma, 
central obesity was strongly and significantly related to risk [Ng , et al 1997]. Women in 
the highest quintile of waist-to-hip ratio were >9 times (95% confidence interval, 4.6-
17.5) more likely to develop breast carcinoma compared with women in the lowest 
quintile (p=0.0001). In Japanese women in Japan, women who were in the highest quartile 
for body mass index had double (95% CI, 1.49-2.03) the risk for breast carcinoma 
compared with women in the lowest quintile [Hirose, et al 1999]. Furthermore, they found 
that weight gain in later life was associated positively with risk for breast carcinoma, 
regardless of body mass index in early adulthood.  
 
These studies are consistent in indicating that postmenopausal obesity is associated with 
the increased risk [Dewaard F, Baanders-van Halewijin E, 1974]. This may be due to 
increased peripheral estrogen production in postmenopausal women who have more 
adipose tissue, and therefore it increases the breast cancer risk. But this relationship is not 
observed in premenopausal women.  
 
Height was associated with breast cancer among women of Japanese ancestry but not 
among Caucasian women living in the United States [Kolonel, et al, 1986]. Whereas it has 
been proposed that height is related to breast cancer risk primarily in populations where 
inadequate caloric intake in childhood and adolescence limits growth, it appears that taller 
women in some populations with a sufficient food supply also experience a higher breast 
cancer risk [Hunter, et al, 1993]. Possibly, inherited patterns in endogenous hormones and 
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growth factors determine the height reached after puberty and at the same time contribute 
to the promotion of breast carcinogens.  
 
Physical activity in adolescence is reported to decrease risk, perhaps due to a higher rate 
of anovulatory cycles [Frisch R, et al, 1981; Bernstein L, et al, 1994], but an increased 
level of physical activity later in life has not been shown to reduce breast cancer risk. 




Based on ecologic evidence and on results from cell and mammal studies [Adlercreutz, et 
al 1990], the role of isoflavones contained in soy products [Adlercreutz, et al 1990; 
Messina, et al, 1991; Nomura, et al 1978; Wu et al, 2002] has been investigated in breast 
cancer prevention.  
 
A case-control study among Asian-American women [Wu, et al 1996] detected a 30% 
decreased risk of breast cancer for women who reported eating tofu more than once a 
week as compared to women who ate tofu less than once a month. The estimated relative 
risk for breast cancer was 0.4 in a study from Singapore [Lee, et al 1991] when 
premenopausal women who consumed 55 g or more soy products per day were compared 
to women who consumed less than 12 g of soy products per day, but these results were not 
confirmed in a Chinese study in Shanghai and Tianjin  [Yuan, et al 1995]. Although fruit 
and vegetable intake may protect against breast cancer [Freudenheim, et al 1996], the low 
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fruit and vegetable intake in Japan make it an unlikely candidate to explain the low breast 
cancer risk in this population.  
 
2.1.5 Immigrant studies 
 
Studies of migrants suggest that the environment is an important factor that is responsible 
for the variation in breast cancer rates among countries. However, the speed with which 
incidence rates among migrants and their offspring approach those of their adopted 
country has varied considerably from one study to another and from one ethnic group to 
another. 
 
 One study [Buell, et al, 1973], for instance, found that first-generation Japanese migrants 
to the United States had slightly higher breast cancer incidence rates than women in Japan, 
but incidence rates in second-generation migrants, who were potentially exposed to a new 
environment and culture at an early age, increased more markedly.  
 
The pace of accumulation may differ among various ethnic groups. The slower rises in 
breast cancer rates among Japanese, Chinese, and Mexican migrants to the United States 
and their offspring as compared with Polish migrants suggested to another group of 
investigators [Thomas, et al, 1987] that either some protective factor in the former cultures 
is carried over into the second generation or that some risk factor for breast cancer is 
avoided by these second-generation individuals, as well as by their migrant parents.  
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A study in Los Angeles [Shimizu, et al, 1991] found that the age of migration of Asians 
and Hispanics affects risk: those who migrated at an early age had much higher incidence 
rates than those who migrated in adulthood, a finding which suggests that either some 
exposure early in life or total years since migration is of etiologic importance. These 
observations are interesting and suggestive, but the difficulties in studying them have 




Recent studies have suggested that about 10% of breast cancer cases are directly due to 
inherited mutations in breast cancer related genes and that most of these result from 
mutations of the BRCA1 and BRCA2 genes. Normally, these genes help to prevent cancer 
by making proteins that keep abnormal cells from growing. However, if a person has 
inherited a mutated gene from either parent, chances of developing breast cancer increase. 
About 50% to 60% of women with inherited BRCA1 or BRCA2 mutations will develop 
breast cancer by the age of 70 [Inoue R, et al, 1995]. Women with these inherited 
mutations also have an increased risk for developing ovarian cancer. Inherited mutations 
of the p53 tumor suppressor gene can also increase a women’s risk of developing breast 
cancer, as well as leukemia, brain tumors [Hartmann, et al, 1996]. Recently, Sng et al [Sng 
JH, et al, 2000] has reported data on BRCA1 mutation in Chinese patients will early onset 
breast cancer in Singapore. 
 
With the development of molecular epidemiology [Perera, 1996], so-called biomarkers of 
susceptibility have been identified. Polymorphisms of genes coding for activating (phase 
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I) and detoxifying (phase II) enzymes may be associated with susceptibility to certain 
cancers [Le, et al, 1998].  
 
 In addition to carcinogens [Le, et al, 1998], several dietary agents, e.g., indole-3-carbinol 
[Michnovicz, et al, 1991], isothiocyanates [Shapiro, et al, 1998], and quercetin 
[Obermeier, et al, 1995], appear to be able to induce phase I or II enzymes, thereby 
leading to an interaction between genetic susceptibility and environmental exposure. 
 
2.2 Hypothesis for the relationship of hormonal, reproductive related 
factors and breast cancer incidence rates variation 
 
Several hypotheses have been submitted to explain the relation between hormonal, 
reproductive related factors and breast cancer incidence rates variation. One of the 
hypotheses noted that when the age-incidence curve of breast cancer is plotted on a log-
log scale, the curve produced is not a straight line as it is with other cancers [Pike, et al. 
1983]. Instead, the curve assumes a straight line until approximately age 50 years, when a 
decrease in the slope is noted. This observation has pointed towards the etiology of breast 
cancer and its dependence on female hormones for the induction and promotion of 
carcinogenesis.  
 
2.2.1 Pike’s “Breast Tissue Age” Model 
 
As proposed by Pike’s model [Pike, et al, 1983], the international variations in breast 
cancer incidence may be a result of differences in hormonal, primarily estrogen, exposure 
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leading to aging of the breast tissue according to breast tissue age, rathe r than according to 
chronologic age [Henderson, et al 1982, Henderson et al 1996]. 
 
The physiology of the female breast is dependent on the mammary proliferation effects of 
the ovarian hormones, estrogen and progesterone. Estrogen is primarily responsible for 
elongation and branching of the breast ducts, whereas progesterone is necessary for 
lobular development and maturation [Topper, et al. 1980]. The high levels of circulating 
hormones during pregnancy result in the differentiation of the terminal duct-lobular unit 
(TDLU), which is the major site of malignant transformation in the breast. This process of 
differentiation of the TDLU is protective against breast carcinoma development, and its 
effect is permanent [Russo, et al, 1995]. 
 
The theory of Pike assumes that breast carcinoma incidence rates vary in proportion to a 
power of the accumulated “breast tissue age” [Pike, et al, 1983]. In that model, the breast 
tissue ages at a constant rate between age at menarche and age at FFTP (First Full Term 
Pregnancy) , at which time the hormonal milieu of pregnancy causes a one-time increase in 
breast tissue age but lower the rate of subsequent “ breast tissue aging”. This lower rate 
continues until the perimenopausal years, at which time it decreases linearly until 
menopause. After menopause the breast tissue continues to age, but at a much lower rate. 
This model predicts that at a given age, a woman with an FFTP (first full term pregnancy) 
in the preceding 5-10 years is at increased risk relative to a nulliparous woman. Studies of 
Janerich and Hoff, Lubin et al., and Pathak et al. have confirmed this theory [Janerich, et 
al, 1982; Lubin, et al, 1982; Pathak, et al, 1986]. Carrying a pregnancy to the third 
trimester confers a protective effect on lifetime risk for breast carcinoma if that pregnancy 
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occurs early in life. However, if a women delivers her first child close to the age at which 
menopause occurs, her lifetime risk is actually higher than if she was nulliparous. 
 
2.2.2 Pathak and Whittemore’s model  
 
Pathak and Whittemore [Pathak, et al, 1992] extended Pike’s single-birth model to a 
multiple-birth model, by incorporating a smaller increase in risk at each additional full 
term pregnancy with a subsequent lowering of the rate at which breast tissue ages. Rosner 
et al. [Rosner, et al, 1994] fitted the extended Pike model to prospective data from the 
Nurses’ Health Study and obtained breast carcinoma incidence curves for various 
combinations of age at FFTP, total parity, and ages at subsequent births. Based on his 
model, the predicted breast carcinoma incidence rates started at age 30 years up to age 70 
years for nulliparous women, women with 1 birth at age 20 years, women with 2 births at 
ages 20 and 23 years, and women with 3 births at ages 20, 23, and 26 years. The predicted 
incidence curves for these hypothetical scenarios show lower risk for nulliparous women 
relative to multiparous until ages 42-45 years, at which time a crossover in incidence 
occurs and the multiparous are at a lower risk relative to the nulliparous women. The 
crossover for women with a single birth at age 20 years does not occur until age 55 years. 
This shift to a later age for the crossover effect for women with a single birth relative to 
multiparous women would be expected based on the hypothesized decreased rate of breast 
tissue aging after each subsequent pregnancy. 
 
2.2.3 Effect of hormones on carcinogenesis 
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Hormones induce carcinogenesis by inducing cell proliferation, which is an essential 
component of carcinogenesis [Pike, et al, 1993]. This hypothesis is explained by the 
observation that increased cell proliferation results in a larger pool of cells that are 
susceptible to defective DNA repair. This in turn leads to mutations, which are 
subsequently propagated through increased mitotic activity present in proliferating cells 
[Preston, et al, 1990], and can result in cancer formation. In contrast, differentiation of 
cells in the terminal duct-lobular unit (TDLU), produces the long term effect of slowing 
the cell cycle in the epithelial cells of this location, which allows more time for DNA 
repair, which in turn will lead to decreased carcinogenesis [Colditz, et al 1995].  
 
2.3 Ethnic variation in breast cancer and its association with hormonal 
related risk factors 
 
There are considerable differences in the incidence rates of breast cancer in different 
populations. The incidence rate in Singapore is about one-third of that of American 
women and half that of European women. It is estimated that while an American woman 
has a 12% chance of developing breast cancer in her lifetime, in Singapore the chance is 
lower, estimated at 4 to 5% [Parkin et al, 1992]. The high-risk group is composed 
predominately of white population. The low risk group is composed predominantly of 
Asian and African populations. The intermediate group is made up of westernized blacks 
and populations of Latin extraction. The Asians have low rates if they remain in their own 
country but acquire higher rates if they migrate geographically like the Japanese 
Hawaiians. This distribution is therefore telling us that the determinant is obviously not 
only geography but also diversity in the groups of women. 
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2.3.1 Ethnic variation of breast cancer incidence rate 
 
Figure 2.3.1 illustrates the marked variation in the age standardized incidence rate of 
breast cancer among different countries between 1988 and 1992 [Chia, et al, 2000]. The 
incidence rate of breast cancer in Singapore was lower than UK (77.8 per 100,000), US 
and other western countries. However the women of all the three major ethnic groups 
(Chinese, Malay and Indian) in Singapore had higher age standardized breast incidence 
rates than other Asian countries. For example, the incidence rates in Singapore were 
higher than their corresponding ethnic group in Shanghai of China (26.5 per 100,000) and 
Madras of Indian (23.5 per 100,000). 
 
Breast cancer incidence has been increasing in women all over the world. In the 
multiethnic study in Hawaii, over the last forty-years, significant increases in breast 
cancer risk have been observed in all ethnic groups except Chinese [Galanis, et al, 1998]. 
Although breast cancer risk in Hawaii among women of Japanese and Filipino ancestry 
remains lower than among Caucasian women, Japanese and Filipino women experienced 
a greater increase in risk than did Caucasian women.  While the risk approximately 
doubled for Caucasian and Native Hawaiian women, it quadrupled for Japanese women 
and tripled for Filipino women. The limited data available for Chinese, who constitute less 
than 10% of Hawaii’s population and who have intermarried frequently with Native 
Hawaiian, suggest that the risk in that population has changed very little over the last 
thirty years. The reason for this is unknown. 
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Figure 2.3.1 Female Breast Cancer: International comparisons-age-standardized 

































Source: Chia, et al, 2000 
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In addition, comparisons among population at low and high risk for beast cancer have 
noted significant difference in the shape of the age-specific incidence rates [Haenszel, et 
al 1973; Buell, et al 1973; Wynder, et al 1991]. Among Caucasian women, the increase in 
incidence rates levels off with age during the menopausal years, followed by a continued 
but slower rise during the postmenopausal years, whereas in Japan breast cancer incidence 
rates remain almost constant or even decline after menopause. 
 
2.3.2 Ethnic diversity of breast cancer related risk factors 
 
Ethnic variation in breast cancer is associated with many risk factors. Some of risk factors 
are related with modern lifestyle induced factors, such as not having children, oral 
contraceptive use, hormone replacement therapy, not breast-feeding, obesity and high-fat 
diets etc.  
 
Brinton et al. [1997] observed a pattern of association for age at first full term pregnancy 
(FFTP) in black and white women ages 20-39 and 40-54 years in 1990-1991. Although 
late age at FFTP increased the risk for black women ages 20-39 years (comparing FFTP 
prior to age 20 years), no such increase was observed for the group ages 40-54 years. For 
white women, this pattern of association was almost reversed, with only a slight increase 
in risk with increasing age at FFTP for women ages 20-39 years and a substantially higher 
increase in risk for the group ages 40-54 years.  
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For total parity, Brinton et al. [1997] found a protective effect of high parity in both age 
subgroups of white women and only in the group of black women ages 40-54 years.  
 
Frank D. et al [1998] conducted a population-based case-control study of breast cancer in 
Hispanic and non-Hispanic white women in New Mexico. They found that age at 
menarche, menopausal status, and age at menopause did not have strong influences on the 
risk of breast cancer among Hispanics or non-Hispanic whites, but they identified that 
parity, age at FFTP, and duration of lactation were independently associated with the risk 
of breast cancer in Hispanic women. The effect of parity and duration of lactation on the 
risk of breast cancer varied by ethnicity. Reproductive factors explained 17 percent of the 
ethnic difference in incidence for postmenopausal women and none of the difference 
among premenopausal women. 
 
Few studies have focused on multicultural differences and the relation between hormonal 
risk factors and breast cancer. It is critical that these be done not only to provide 
information to promote public health in diverse population, but also to provide further 
insight into breast cancer etiology. It is likely that the metabolism of hormonal factors 
varies among populations according to genetic differences, and research into this 
possibility may help unravel the complicated puzzle of carcinogenesis. In this regard, 
further modeling of the crossover effect of breast carcinoma incidence among different 
ethnic women needs to be done. Risk factor profiles need to be compared and contrasted 
among the major ethnic population. These should include major endogenous hormonal 
risk factors, such as age at menarche and menopause, age at onset of regular menstrual 
cycles, effect of infertility, spontaneous or induced abortion, age at delivery, interval 
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between deliveries, parity and lactation duration. Exogenous hormonal use and its 
investigation are also critical and should include study of the use and duration of oral and 
parenteral contraceptives and postmenopausal HRT. In this regard, investigation of 
different hormonal formulations, their effects on circulating hormone levels, and their 
differential effects on risk in various populations is urgently needed. All of these studies 
should incorporate the field of molecular epidemiology, in hopes of discovering insights 
into the biologic mechanisms involved in observed epidemioglical risk factors among 
multicultural populations. 
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Chapter 3  Materials and Methods 
 
The trends in breast cancer incidence were obtained from the published data (see below 
3.1.2) and plotted according to the three different ethnic groups in Singapore: the Chinese, 
Malay and Indians. Various calculations and computations were then made (see below 
3.1.3) in order to obtain standardized data and to make comparisons between the three 
ethnic groups. The annual percentage change in incidence rate was also calculated for the 
three different ethnic groups to investigate if there were any differences between the 
ethnic groups (See 3.1.3.2). The birth cohort effect was also plotted to investigate for 
difference between the three different ethnic groups (see 3.1.3.3). 
 
Finally, a small pilot case-control questionnaire study was carried out in the oncology and 
medical outpatient clinics at the National University Hospital. The aim of the 
questionnaire was to study the possible risk factors of breast cancer in patients with breast 
cancer. Despite the small number acquired, such a study was still considered useful and 
important as a pilot study to suggest further more detailed studies.  
 
3.1 Primary Study 
 
3.1.1 Procedures for the registration of cancer in the Singapore Cancer 
Registry  
 
Founded in 1967, the Singapore Cancer Registry is a national population based registry 
that is responsible for the collection, storage and analysis of basic clinical and 
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epidemiological data on all cancers diagnosed in Singapore. The registry is supported 
from the National University of Singapore, the Ministry of Health, the Singapore Cancer 
Society and the International Agency for Research on Cancer.  
 
Registration is primarily based on notifications received from all sections of the medical 
profession in Singapore. To ensure that registrations are as complete as possible, the 
Registry routinely checks pathological records, hospital discharge records and death 
certificates (inclusive of private hospitals and laboratories). Cancer cases picked up from 
these sources are checked against previously registered cases. If the cases were not 
previously notified, reminders are sent to the doctors-in-charge for more information. 
Requests for clarification or additional information are also sent whenever necessary. 
When cases picked up from pathological records, hospital discharge records and death 
certificates are not notified by doctors, even after special request, they are registered by 
Registry staff provided they satisfy one of the following conditions, a pathological 
diagnosis of cancer, a clinical diagnosis of cancer supported by surgical, radiological or 
laboratory findings, or mention of cancer in the death certificate. 
 
To ensure that the information provided by the Registry is of a high quality in terms of 
coverage and accuracy, a number of quality control checks are conducted. Registry staffs 
seek to rule out missed cases, duplicate notifications and inaccurate data. National 
Registration Identity Card (NRIC) number helps to ensure proper coverage and eliminate 
duplicate reporting effectively. In this way, close to complete coverage is ensured, as 
Singapore is a small country with good communication links. 
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3.1.2 Source of Data 
 
The number of cases and incidence rates by age group of breast cancer were obtained 
from the Singapore Cancer Registry Report No.4 [Chia et al, 1996] and No. 5[Chia et al, 
2000]. The Singapore Cancer Registry is a population-based registry covering the entire 
resident population of Singapore (Citizens and permanent residents). The population 
denominators in the reports were based on the censuses of 1970, 1980 and 1990, 
respectively. [Lau, 1992].  
 
The Registry followed the international classification of Diseases for Oncology, 2nd 
Edition (ICD-0) (Report No.5) and 9th Revision (ICD-9) of international classification of 
Disease for the classification of Primary sites and morphology (Report No.4). 
 
3.1.3 Data Analysis 
 
3.1.3.1 Truncated standardized incidence rate 
 
To obtain the truncated standardized incidence rates, each five -year age group-specific 
incident rates were acquired from the Singapore Cancer Registry Report initially, and then 
they were adjusted for age using the “world” population by the Direct method 
(Waterhouse 1996), the expected incidence rates were calculated. Figures for world 
population were obtained from Cancer Incidence in Five Continents [Waterhouse, et al, 
1993]. We combined the expected rates for the pre-menopause group to include 25 to 54 
years old and the post-menopause group to include all from 55 years old and above, 
respectively. Table 3.1.1 showed the details. The methods of computation of truncated 
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standardized incidence rate of other each 5-year period by ethnicities were as same as that 
of 1968-1972, which allowed figures to be comparable between populations and over 
time. 
Table 3.1.1 Example of computation of truncated standardized incidence rate of 




population CHINESE ExpectC MALAY expectM INDIAN expectI 
1968-1972 25- 8000 2.8 0.224 5.1 0.408 5.8 0.464 
1968-1972 30- 6000 11.1 0.666 8.3 0.498 15.2 0.912 
1968-1972 35- 6000 21.4 1.284 27.7 1.662 12.8 0.768 
1968-1972 40- 6000 36.8 2.208 24.1 1.446 46 2.76 
1968-1972 45- 6000 46.2 2.772 44.3 2.658 33 1.98 
1968-1972 50- 5000 60.7 3.035 45.2 2.26 35.2 1.76 
total  37000  10.189  8.932  8.644 
25-54y ASR    27.53784  24.14054  23.36216 
1968-1972 55- 4000 62.2 2.488 58.9 2.356 70.5 2.82 
1968-1972 60- 4000 63.9 2.556 50.4 2.016 44.4 1.776 
1968-1972 65- 3000 66.3 1.989 78.1 2.343 67.9 2.037 
1968-1972 70- 2000 59.8 1.196 29.1 0.582 247.2 4.944 
1968-1972 75- 1000 45.1 0.451 67.5 0.675 0 0 
1968-1972 80+ 1000 59.9 0.599 0 0 483.1 4.831 
total  15000  9.279  7.972  16.408 
>=55y ASR    61.86  53.14667  109.3867 
Data calculated from Singapore Cancer Registry Report No.4 & No.5 [Chia, et al 1996 
&2000]. 
 
3.1.3.2 Annual percentage change in incidence rate 
 
To obtain age-adjusted average annual percentage change for the estimation of trends 
across individual calendar years, data were analyzed by generalized linear regression 
model for discrete data. 
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When the number of cases occurring in different periods are known and if the logarithm of 
incidence varies linearly between two periods, the rate of change can be estimated by the 
slope of the line which best represents the logarithm of incidence as a linear function of 
period of diagnosis. The assessment of fit of this model was based on the Maximum 
Likelihood method. 
 
The Poisson regression procedure uses an age-period model to calculate age-adjusted 
average annual percentage change according to the equation: 
Log (rate)=agei+ b* (period) 
With i = 5,6… 16, where there are 12 age groups (20-24, 25-29, …,  >=75), and period was 
given as 1,2… 6 (period 1 is 1968-1972, period 2 is 1973-1978 up to 1993-1997). This 
analysis was performed separately in different ethnic groups. The regression coefficient b 
is the increase in log of risk per five-year period. For example, if b=0.1620 (SE=0.001) for 
Chinese breast cancer, rate of change by 5-year period is the value of (eb-1) or 0.1759. To 
obtain a time trend per year instead of per five-year period, we simply divide b by 5, 
getting 0.03518. We convert this trend to a relative risk of Exp(0.03518)=1.036, 
indicating an annual increase of 3.60%. To investigate the effect of ethnicity on breast 
cancer incidence rate, ethnic characteristic was added to the equation as covariate to 
calculate the relative risk and its likelihood-based 95% confidence interval. The 
calculations were carried out with the software SPSS, using a General Log linear 
Analysis. The analysis was performed separately by ethnicity. 
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3.1.3.3 Birth cohort plotting 
 
In order to show the changes in time and inter-ethnic differences, the birth cohorts of age-
specific incidence of breast cancer of each ethnic group were plotted. The data of age-
specific rates were also used from the Singapore cancer registry. Age at diagnosis was 
adopted in the middle of the range in each five-year from 1968-1997, and the age-specific 
rates were obtained from those births between 1905 and 1950. All the data were shown as 
a series of longitudinal view rather than a series of cross-sectional view. Table 3.1.2 gives 
an example. The other two ethnic groups were plotted in the same way. 
 
Table 3.1.2  Age-specific incidence rate of breast cancer in Chinese women arranged 




  25y 30y 35y 40y 45y 50y 55y 60y 65y 70y 75y 80y 
1905 __ __ __ __ __ __ __ __ 66.3 86.9 90.4 97.9 
1910 __ __ __ __ __ __ __ 63.9 68.7 83.1 80.1 124.5 
1915 __ __ __ __ __ __ 62.2 80.1 79.5 93.6 117.5 114 
1920 __ __ __ __ __ 60.7 65.8 86.5 103.2 105.1 98.7 __ 
1925 __ __ __ __ 46.2 53.5 72.9 76.3 124.9 115.6 __ __ 
1930 __ __ __ 36.8 60.6 67 87.2 105.9 164.7 __ __ __ 
1935 __ __ 21.4 36.6 71 81.9 100.6 117.5 __ __ __ __ 
1940 __ 11.1 31.4 64.8 102 110.8 151.2 __ __ __ __ __ 
1945 2.8 11.1 37.6 60.9 125.2 149.3 __ __ __ __ __ __ 
1950 5.3 13.3 46.2 91.2 185.3 __ __ __ __ __ __ __ 
 
Data derived and calculated from Singapore Cancer Registry. [Chia, et al 1996 &2000]. 
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3.2 Case-control study 
 
The study was a hospital-based case-control study, which adopted incident cases and 
returning visit cases of breast cancer as cases and non-cancer patients visiting the same 
hospital as controls. All the consecutive cases and controls were recruited from National 
University Hospital (NUH) from May 1, 2001 to Feb 1, 2002. The case-control study 
comprised of 242 breast cases and 274 controls respectively. Based on ethnic difference, 
we separated the cases and controls into 3 groups: Chinese, Malay and Indian.  
 
The risk factors were assessed by interview, using a multiple-choice questionnaire. The 
structured in-person interviews, which lasted a median of 25 minutes, collected detailed 
information regarding demographic factors, reproductive and menstrual history, 
contraceptive behavior, use of exogenous hormones, traditional medicine and screening 
history, anthropometrics and family history of cancer, alcohol consumption and smoking. 
 
3.2.1 Data Collection 
 
3.2.1.1 Selection of Cases 
 
A case of breast cancer was defined as a histological confirmed carcinoma of the breast 
occurring in a Chinese/ Malay/ Indian female attending as outpatient or as an inpatient at 
the National University Hospital (NUH) from 1 May 2001 to 1 Feb 2002. 
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The criteria for eligibility of cases were female with primary carcinoma of the breast 
diagnosed in NUH (confirmed by screening mammography or biopsy), who were between 
the age of 18 and 75 years old, who lived in Singapore at least 5 years, who were mentally 
alert and coherent in their response to questions, and who gave consent for interview and 
tracing of records. Subjects who were subsequently determined to be suffering from 
cancer of another site, or who died from another cancer have not been included. Subjects 
who were not clearly diagnosed as primary breast cancer were also excluded. 
 
Each subject was interviewed in the ward or at the specialist clinic (medicine, oncology, 
surgery) by the investigator, and a six-paged questionnaire was administered in person. 
 
During the study period, completed interviews were obtained from 242 of the 276 eligible 
cases (87.7%) and 274 of the 284 eligible controls (96.5%). Reasons for non-interview 
included subjects refusing to provide interview information (4.8% in cases vs. 1.4% in 
controls) and serious illness (3.3% in cases vs. 1.8% in controls). Among cases, Chinese 
had slightly lower response rates than Malay or Indian subjects. 
 
3.2.1.2 Selection of controls 
 
Controls were selected from National University Hospital patients, frequency-matched by 
10-year age group. For each case, one or more hospital controls were selected. Patients 
eligible to act as controls were Chinese/ Malay/ Indian females between 18 and 75 years 
of age. Controls who had disease in the breasts, gynaecological organs or endocrine 
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glands were excluded. Eligible controls were recruited into the study sequentially, from 
medicine and surgery specialist clinics. 
 
3.2.1.3 Measurement of exposure  
 
3.2.1.3.1 Study Instrument 
 
A 6-paged questionnaire was developed and applied in a standardized manner to both 
cases and control subjects. Before administering the questionnaire, the purpose of the 
survey was explained to respondents, using the term “Women’s health study” with no 
reference to breast cancer. 
 
A copy of the questionnaire is attached in appendix. The questionnaire elicited 
information on demographic characteristics, menstrual history and reproductive history, 
oral contraceptive use and hormone replacement therapy history, socio-economical status, 
family history of cancer and benign breast disease history, smoking history and alcohol 
consumption history. Only the variables relevant to the present study will be described 
below. 
 
Menopausal status was classified as premenopause, natural postmenopause, unnatural 
postmenopause, which including surgical (history of hysterectomy with or without 
oophorectomy) menopause, or chemical therapy menopause. Menopausal status was 
classified at the date of interview for controls, and at the date of cancer diagnosis for 
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cases. Women were classified as premenopausal if they had had a menstrual period within 
1 year of the reference date and were not taking estrogens at the time.  
 
A question on the outcome of pregnancy was also included. Women were considered to 
have “full-term delivered” only if the gestational at period was more than 36 weeks; if the 
gestational period was more than 28 weeks and less than 36 weeks, this was considered to 
be a “premature delivered baby”; spontaneous abortion was considered “miscarriage”, 
medical or surgery induced abortion was considered “abortion”. 
 
For the question of current body weight and height, the same investigator throughout the 
whole study period did measurements. Body weight (kg) in light clothes and height (cm) 
without shoes were determined to the nearest one decimal point using the SECA Balance 
with a height attachment. Body Mass Index (BMI) was then calculated using the formula:  
BMI= weight (kg) ÷ Height (m) ².  
BMI of less than 18.5 kg/m2 was taken as underweight, 
18.5 kg/m2 to 24.9 kg/m2 as healthy weight range,  
25.0 kg/m2 or more as overweight. 
 
Respondents were classified as having a history of benign breast disease if they gave a 
positive answer when asked if they had “ever had” the disease. A positive family history 
of cancer was defined as a “yes” response to “has anyone in your family ever had 
cancer?” and if that person was a first-degree relative, or relative other than husband/ 
husband’s family.  
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3.2.1.3.2 Techniques to reduce bias 
 
It is widely accepted that one of the chief sources of systematic differences in the case-
control study is that arising from bias in measuring exposure. In order to minimize this, it 
was considered important that the conduct of the interview, and the responses elicited 
should not be influenced by knowledge of disease status. As far as possible, cases were 
interviewed soon after admission (if in-patients) and before being called to see the doctor 
(if out-patients). 
 
Since recall bias can lead to either an over or underestimation of the association between 
exposure and disease, during our investigation, one of the most common methods of 
gathering information was by interview either of the study subjects themselves and their 
surrogates, such as spouses of participants or sisters of affected patients. However, it is 
thought that women who have breast cancer were more likely to be truthful about the fact 
that they had some risk factors, such as induced abortion, compared to women who do not 
have breast cancer. 
 
A second type of systematic error in collecting information is interview bias, which refer 
to any systematic difference in the soliciting, recording, or interpreting of information 
from study participants. Since in a case-control study, knowledge of a subject’s disease 
status may cause differential probing by the questioner for previous exposure history, this 
may cause bias regarding exposure history. Consequently, prevention of bias in the design 
phase of the investigation is crucial to the validity of the study results; it means that highly 
objective, closed-ended questions for subjects were very important. In addition, since 
Part I  - 37 - 
information concerning a subject’s exposure status was available at the time and disease 
status was determined, investigators who were aware of the study hypothesis may be more 
or less likely to record the outcome of interest for individuals known to have the exposure 
under examination, the questionnaire we provided contains mainly questions that are not 
open and could be completed by subjects themselves. In the case of questions that need 
some explanation (A pilot study had been done before the case-control study), we 
furnished clear and detailed definition of some exposures in the protocol (See 3.2.1.3). 
 
Another source of bias in the study concerns the potential for loss of subjects to follow-up 
due to some reason. Even though it is not so important for our case-control study as that in 
a cohort study, any observed association would be biased if persons are lost to follow-up. 
As mentioned, patients were therefore followed up till the diagnosis was verified. If the 
diagnosis could not be verified by the time of ending of the study (1 Feb 2002), the data 
was used to check for measurement bias only, and was not used in the final analysis. 
 
For this study, one control with a history of breast cancer was removed from the analysis. 
In addition, 3 cases that indicated on interview that they did not have the minimal 5-year 
residency in Singapore were also eliminated from analysis. To reduce effects of detection 
bias, we eliminated 12 cases diagnosed as breast cancer combined with cervical, uterus or 
ovarian cancer. 
 
With respect to the administration of the data collection instrument, the single most 
important way to minimize the potential for bias was to maintain blindness to the greatest 
possible extent. In practical terms, in order to blind subjects, we named our questionnaire 
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“Women’s health research”, which means, subjects would be unaware of an individual’s 
disease status when assessing exposure in this study. 
 
3.2.1.3.3 Control of confounding factors in the design and analysis 
 
Confounding involves the possibility that the observed association is totally or in part due 
to the effects of differences between the study groups other than the exposure under study 
that could affect their risk of developing the outcome of interest. Since confounding can 
lead to an overestimate or underestimate of the true association between exposure and 
disease and can even change the direction of the observed effect, it is very important to 
control confounding in two phases of the questionnaire: design and analysis. 
 
a. Methods to control confounding in the design 
Confounding cannot occur if the potential confounding factors do not vary across either 
the exposure or the disease categories. One way to achieve this is to restrict the 
admissibility criteria for subjects and limit entrance into the study to individuals who fall 
within a specified category or categories of the confounder. For example, in our study, as 
race was a potential confounding factor; the study could include only Chinese, Malay and 
Indian women, and excluded completely other races. In addition, obesity was another 
potential confounding factor, and since some endocrine disease were associated with 
obesity, hence, we excluded those women who had diabetes in our subjects. 
 
b. Methods to control confounding in the analysis 
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Stratification is a technique to control confounding in the analysis of a study that involves 
the evaluation of the association within homogeneous categories or strata of the 
confounding variable. For example, as ethnicity is a potential confounder, an estimate of 
the association between the exposure and disease would be calculated for Chinese, Malay 
and Indian women separately. Each of these stratum-specific estimates is, by definition, 
unconfounded by ethnic, since there is no variability of the confounding variable within 
the stratum. 
 
Multivariate analysis allows the efficient estimation of measures of association while 
controlling for a number of confounding factors simultaneously even in situations where 
stratification would fail because of insufficient numbers. In general, a multivariate 
technique refers to any analysis of data that takes into account a number of variables 
simultaneously. The most common way that many factors are controlled for 
simultaneously is through the use of a multiple regression model. In our study, the 
outcome of interest was a binary variable such as breast cancer versus non-breast cancer. 
In such circumstances, it was possible to use a specialized type of logistic regression 
analysis, which was a powerful statistical tool for estimating the magnitude of the 
association between an exposure and a binary outcome after adjusting simultaneously for 
a number of potential confounding factors. This model is a simple variant of the multiple 
regression equation, in which the risk of developing an outcome is expressed as a function 
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3.2.2 Data Analysis 
 
Bivariate odds ratios (OR) for risk of breast cancer and 95% confidence intervals (95% 
CI) were calculated for ethnic status, and for each of the variables of interest (Breslow and 
Day 1980). P value of 0.05 or less was accepted as significant. Mean values (±S.D.) were 
analyzed by ethnicity and age group. Logistic regression analysis was then employed 
using Enter approach to control potential confounding factors, and to select the significant 
independent variables (covariates). This was done by computing Odds ratio [Benichou 
and Gail; 1990] and associated 95% Confidence Intervals. Procedures from the SPSS 
software package version 10.0 (SPSS Inc., Chicago, IL) were used. 
 
Part I  - 41 - 
 
Chapter 4 Results 
 
The results are presented in three parts below. In sections 4.1 and 4.2, the observed data 
illustrates the significant increasing trend of breast cancer in Singapore over the past 30 
years and the different patterns of increase among Chinese, Malay and Indian groups 
separately. In the section 4.3, the case-control study displays the magnitude and 
differences of some known and identified risk factors in subjects by ethnic group.  
 
 
4.1 Breast cancer incidence trend in Singapore 
 
 In Singapore, the absolute annual incidence number of medically certified breast cancer 
patients showed an increasing trend in the 30 years from 1968 to 1997. The age-adjusted 
incidence rate per 100,000 also showed an increase from 19.5 per 100,000 women in 
1968-1972 to 46.1 per 100,000 women in 1993-1997 (Fig 4.1.1). This age -adjusted 
incidence rate of breast cancer in 1993-1997 is 2.3 times than that in 1968-1972. There 
has been a consistent increase over time across all age -specific groups.  
 
Figure 4.1.2 displays the age-adjusted rates for each 5-year period of all Residents of 
Singapore women. It can be seen from the figure that there is an increasing pattern across 
each age-specific group. 
 
The bimodal age distribution of Singapore female subjects with breast carcinoma can be 
observed in each 5-year period line. The two peaks are in the 45 to 49 years age group and 
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at about 65 years age. This graph has the same character as in other Asian countries, such 
as China and Japan [Tao, et al, 1988], with a tendency to display a “plateau” between 50 
to 60 years. After 60 years of age, the age-specific breast cancer risk increases again. 
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4.2 Ethnic difference incidence Rate of breast cancer among three 
ethnic groups 
 
Chinese, Malay and Indian are the three main ethnic groups in Singapore. In the 
population, the proportion of the three ethnic groups is 77.7%, 14.1%, and 7.1% 
respectively (1990 census). From the data of the Singapore Cancer Registry, it can be 
noticed that while there are increasing trends present in all three ethnic groups, there are 
some different characteristics between the three groups. 
 
The number of medically certified incidence of breast cancer was the highest among the 
Chinese, followed by the Malays and Indians. However, when compared with the total 
female population of all races in Singapore, there was no statistically significant 
difference in the percentage of Chinese having breast cancer (Table 4.2.1). 
 
From Table 4.2.2, it can be seen that all three ethnic groups show an increase in incidence 
of breast cancer over the past three decades. The greatest increase was in the Malay group, 
followed by Chinese group. Indian women have the lowest rate of increase, although the 
small number of cases makes interpretation of the overall trend difficult. 
 
In Singapore, the incidence in 1988-1997 in Chinese (43.3 per 100,000) and Malay 
women (37.6 per 100,000) appeared to be higher than Indian women (34.3 per 100,000). 
Indian women thus have a lower incidence of breast cancer compared with the other two 
main ethnic groups in Singapore in the last decade. 
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Table 4.2.1 Number of cases (age-standardized incidence) of breast cancer 
by ethnic group 





































































Table 4.2.2 Average annual percentage changes in incidence by ethnic group 
Ethnic Group Average annual 
Change 
95% CI 
All groups 3.5% 3.1%, 3.9% 
Chinese 3.6% 3.3%, 3.9% 
Malay 4.0% 2.3%, 5.8% 
Indians 1.4% 0.9%, 2.0% 
Source: Singapore cancer registry (Chia, et al, 1996& 2000) 
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4.2.1 Age and race incidence 
 
Between 1993-1997, the median age at presentation in Chinese women is 52.5 years with 
mean age 53.58 ± 0.23 years compared with a median age of 47.5 years in Malay women 
with mean age 49.86±0.66 years and a median age of 52.5 years in Indian women with 
mean age 53.7±1.00 years. This shows a similarity in median age in the two ethnic groups 
of Chinese and Indian women at the age of presentation, while Malay women have a 
statistically significantly lower median age (P<0.05, t-test). 60% of Chinese women are 
less than 55 years compared with 67.4% of Malay women and 53.8 % of Indian women. 
The two differences suggest that Malay women have breast cancer at a younger age than 
that in Chinese and Indian women. It also can be seen that the median age of breast cancer 
in all three ethnic groups of Singapore women are much younger than that in Western 
women whose the median age is 60-64 years [Kelsey, et al, 1993]. Studies in Japan and 
China also show a younger mean and median age of presentation in these countries [Tao, 
et al, 1988]. These suggest that breast cancer presents at a younger age in Asians. 
 
4.2.1.1 Trend and age incidence  
 
In Fig 4.2.1, the incidence rate increases till about 47 years old in Chinese women. The 
period with highest rate is 45-50 years. The rates then tend to decrease in the older age 
groups. There are two peaks in breast cancer incidence in Chinese women. The highest 
peak is at 47 years, and the second peak is at 65-70 years old. 
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As Fig 4.2.2 shows, Malay women show a difference in the change in incidence rate, the 
increasing trend is not similar to that of the Chinese group. Each line only has one peak. In 
addition, the peak in Malay group is different in different lines. This may be partly due to 
the smaller denominator of Malay women, but the consistency of the “double-peak” in 
Chinese women is not present. 
 
In Figure 4.2.3, the difference in Indian women is also clear: the highest peaks are after 65 
years old in all the incidence rates. 
 
4.2.1.2 Menopause status and ethnic incidence  
 
The Chinese group had the highest incidence rate in premenopausal women. In contrast, 
the Indian incidence rate was the highest in the postmenopausal women. 
 
To further investigate the relationship of menopause to the incidence of breast cancer, we 
divided the risk population into two groups, the pre-menopause group: 25 to 54 years old 
and the post menopause group 55 years old and older. 
 
Fig 4.2.4 shows an increasing trend in the incidence rate in all three ethnic groups. This is 
to say, in the younger than 55 years old women, or pre-menopause women, incidence rates 
of breast cancer increased with time. The Chinese had the highest incidence rates, 
followed by Malays and Indians. However, the pre-menopause Indian women group has 
an obvious difference in the lower increase in breast cancer incidence compared to the 
Malay and Chinese groups. 
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Fig 4.2.5 shows a contrasting trend in the 55-year and older age compared to the pre-
menopausal group. The Indians have the highest incidence and the Chinese group has 
gradually and recently increased to catch up with similar incidence rates of the Indian 
post-menopausal group. 
 
4.2.1.3 Birth cohort effect  
 
Figure 4.2.6-4.2.8 are plotted to show the age-specific incidence of breast cancer by birth 
cohort from 1968-1997 in three main ethnic groups in Singapore. 
 
The figures represent the data as a series of longitudinal studies rather than before, a series 
of cross-sectional studies. This longitudinal view of the data is also emphasized on a linear 
scale in a plot of the incidence rates of breast cancer against age for each birth cohort. 
 
When the age-specific trends are plotted according to cohort year of birth, breast cancer 
risk in the Chinese group appears to increase among the older women born after 1905 
(Figure 4.2.6). Between births in 1905-1930, there is a slow rise, and then a sharp increase 
among women born thereafter. There is a tendency for successive birth cohorts to have 
higher age-specific rates compared with previous cohorts, suggesting a strong cohort 
effect. 
 
The striking differences in the Indian women group suggest some protection against the 
environmental factors that have caused the increase in breast cancer incidence in the 
Malay and Chinese group. In Figure 4.2.7 and Figure 4.2.8, because of the smaller 
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denominator of Malays and Indians, the higher variability makes the trends more difficult 
to interpret. 
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4.3 Case-control study 
 
4.3.1 General information  
 
The case-control study comprised of a total of 242 patients with histologically confirmed 
breast cancer from the National University Hospital, and 274 hospital control subjects of 
the same age distribution as the cases. Not all patients (or controls) agreed to be 
interviewed fully. Reasons for non-participation by ethnicity and case-control status are 
shown in the table 4.3.1. Refusal rates for Chinese women were higher than for Malay and 
Indian women (8.1% vs. 6.6% vs. 8%). Women with breast cancer were more likely to 
refuse to participate than their control counterparts (total of 12% vs. 3.1%). 
 
We compared the age matched Chinese, Malay and Indian control subjects to identify and 
verify expected racial differences in specific variables. The results of the comparisons are 
indicated in Figure 4.3.1. We found that Indian and Malay women had early menarche and 
earlier age of first full-term pregnancy than Chinese. Surprisingly, the mean age of last 
regular menstrual period of Indian women (46 years) was significantly younger than 
Chinese (51 years) and Malay women (50 years) (P<0.05, t-test). We are not aware of any 
previous reports of this difference in age of menopause. 
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Table 4.3.1 Reasons for nonparticipation by ethnicity and case-control status  
Chinese Malay Indian  






































































Others* includes 12 cases who were diagnosed as breast cancer combined with 
cervical, uterus or ovary cancer, 3 cases that did not have at least 5-year residency in 
Singapore and 1 control with a history of breast cancer. 
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4.3.2 Socio-demographic characteristics of the study population 
 
The major socio-demographic characteristics of the study population (breast cancer 
patients and controls) are described in Table 4.3.2. In the breast cancer patients, the age at 
presentation in Malay women was significantly younger (P<0.01), with a median age of 
45.4 years compared with a median age of 53.1 years in Chinese and 54.3 years in 
Indians.  
 
There was no significant difference between cases and controls in the distribution of 
completed education years in the Chinese group. But in the Malay and Indian groups, 
compared with controls, breast cancer patients were more likely to have completed 6-9 
years (72.7% vs. 43.2% and 55.6% vs. 38.7% respectively) of full time education. 
The proportion of living in =5-room house was highest in Chinese compared to Indian and 
Malay (total subjects in each ethnic group). Compared with controls, there was no 
significant difference between cases and controls about living in =3 room house in each 
ethnic group. For other social economic factors, such as family car ownership, breast 
cancer patients were more likely to own a car, but no statistically significant differences 
can be seen in each ethnic group (P>0.05). 
 
In addition, because of the very small number of women who drink alcohol or smoke, no 
significant difference was observed between Chinese, Malay and Indian breast cancer 
patients. Thus these two items do not feature as risk factors in Singapore compared to 
Western countries. 
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Table 4.3.2 Socio-demographic characteristics of breast cancer and controls among 
Singapore women, 2000-2001 
Percentage of distribution of 
cases and controls (Chinese 
women) 
Percentage of 
distribution of cases and 
controls (Malay women) 
Percentage of distribution of 















Age at interview (years) 
<30 0.5(1) 1.5(3)     
30-39 3.8(7) 4.4(9) 6.1(2) 5.4(2) 7.4(2) 6.5(2) 
40-49 15.9(29) 17.0(35) 42.4(14) 43.2(16) 18.5(5) 22.6(7) 
50-59 47.8(87) 46.1(95) 45.5(15) 43.2(16) 25.9(7) 29.0(9) 
60-69 18.1(33) 18.4(38) 6.1(2) 8.1(3) 29.6 (8) 25.8(8) 
>=70 13.7(25) 12.6(26)   18.5(5) 16.1(5) 
Mean (SD) 53.1(10.9) 52.5(11) 45.4(6.5) 45.7(6.7) 54.3(12.9) 53.4(12.1) 
[Total] Mean 52.8 (10.9) 45.6 (6.5) 53.8 (12.4) 
P value 0.64 0.81 0.51 
Marital Status 
Married 86.3 (157) 93.2 (192) 81.8 (27) 100.0(37)  92.6 (25) 90.3 (28) 
Unmarried 13.7(25) 6.8(14) 18.2(6) 0 7.4(2) 9.7(3) 
P value 0.03*  0.87 
Education (years completed) 
=<5 32.4(59) 31.1(64) 24.2(8) 51.4(19) 33.3(9) 32.3(10) 
6~9 46.2(84) 49.5(102) 72.7(24) 43.2(16) 55.6(15) 38.7(12) 
10~15 20.9(38) 18.9(39) 3.0(1) 5.4(2) 3.7(1) 25.8(8) 
>=16 0.5(1) 0.5(1)   7.4(2) 3.2(1) 
P value 0.57 0.06 0.69 
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Table 4.3.2. (Continued) 
Percentage of distribution 
of cases and controls 
(Chinese women) 
Percentage of 
distribution of cases and 
controls (Malay women) 
Percentage of distribution of 



















23.8(49) 24.2((8) 29.7(11) 29.6(8) 25.8(8) 
4-room house 25.3(46) 26.2(54) 54.5(18) 37.8(14) 25.9(7) 38.7(12) 
>=5-room 50.0(91) 50.0(103) 21.2(7) 32.4(12) 44.4(12) 35.5(11) 
P value 0.54 0.75 0.9 
Own a car 
No 61.0(111) 66.5(137) 72.7(24) 86.5(32) 59.3(16) 74.2(23) 
Yes 39.0(71) 33.5(69) 27.3(9) 13.5(5) 40.7(11) 25.8(8) 
P value 0.29 0.23 0.27 
Alcoholic drinking 
Never 91.8(167) 91.7(189) 97.0(32) 100.0(37) 88.9(24) 83.9(26) 
Yes 8.2(15) 8.3(17) 3.0(1) 0 11.1(3) 16.1(5) 
P value 0.99  0.71 
Cigarette smoking 
Never 94.5(172) 94.2(194) 87.9(29) 100.0(37) 96.3(26) 93.5(29) 
Yes 5.5(10) 5.8(12) 12.1(4) 0 3.7(1) 6.5(2) 
P value 0.89  0.64 
*P value less than 0.05 
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4.3.3 Hormonal and reproductive related factors in different ethnic groups 
 
 
Table 4.3.3 shows the comparative results for the racial differences that include 9 
hormonal and reproductive related variables of primary interest. Multivariate odds ratios 
and 95 percent confidence intervals were computed for Chinese, Malay and Indian 
women, and adjusted by age, education, dwelling, family car ownership, smoking and 
alcoholic drinking. The variances of the rela tive risk estimates are greater for Malay and 
Indian women because of the smaller sample size. 
 
Generally, women with breast cancer were more likely to have a lower parity (P=0.08), 
older age at first full term pregnancy (P=0.06) or null pregnancy (P=0.08) compared with 
control women.   
 
In the distribution of menstrual cycle length (days), a shorter menstrual cycle of less than 
28 days was one risk factor compared with 29-32 days in Chinese group (OR 1.99, 95% 
C.I. 1.29~3.07, P<0.05) and Indian group (OR 4.88, 95% C.I. 1.60~14.86, P<0.05), but 
this was not significant in Malay group, even though the relative risk was 1.35 (95% C.I 
0.47~3.89). There were no significant relationships between age at menarche and breast 
cancer in our subjects, even through the odds ratio of age at menarche younger than 12 
years old was 1.46 (95% C.I. 0.90~2.36) in Chinese group and 1.40 (95% C.I. 0.38~5.26) 
in Indian group. 
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It can be observed that the relative risk of breast cancer among Chinese decreased with 
younger age at first marriage, and increased in unmarried women. The protective factor of 
an age of marriage less than 20 years old was statistically significant (OR 0.41, 95% C.I. 
0.21~0.81, P<0.05). However, when we compared across the 3 ethnic groups of breast 
cancer patients this item, we found that 27.3% of Malay and 40.7% of Indian married at 
the age of younger than 20 years, while only 9.3% of Chinese married at that age 
(P<0.05). 
 
In the distribution of age at first pregnancy (Table 4.3.3.a) (limited to women with 
children), an age of first pregnancy of older than 30 years old was a significant risk factor 
in Chinese women (OR 2.42, 95% C.I 1.32~4.42, P<0.05). By contrast, in the Indian 
group, an age of first pregnancy of younger than 20 years old decreased the risk of breast 
cancer (OR 0.16, 95% C.I. 0.04~0.70, P<0.05). ). In addition, it should be noticed that 
25% of Chinese breast cancer patients were older than 30 years old when they 
experienced the first pregnancy, while the percentage of Malay and Indian were 4.0% and 
9.1%. 
 
A similar pattern of association for Chinese and Malay began to emerge for such factors 
as number of full-term pregnancies (Table 4.3.3.b) (analysis limited to married women) 
and total months of breast-feeding (Table 4.3.3). In the Chinese group, compared to 
women with 1 to 2 life births, women with 3~4 life births had a lower risk of breast cancer 
(OR 0.52, 95% C.I. 0.31~0.86, P<0.05). An even greater protective effect was observed in 
those who had more than 5 life births (OR 0.37, 95% C.I 0.14~0.97, P<0.05). Although 
the Malay group had a similar trend, the statistically significance was not observed, 
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probably due to the limited sample size. For total months of breast-feeding, a dose-
response effect also was seen in the Chinese group, while a general overall protective 
effect was seen in other two ethnic groups, but the small sample sizes of the Indian and 
Malay groups gave a non-significant dose-response effect. However, we still can see some 
differences among these three ethnic groups in these items. Only 31.2% of Chinese breast 
cancer patients have more than 3 children, while the percentage in Malay and Indian are 
55.5% and 52% respectively. In contrast, more than half of Chinese patients (64.3%) have 
null breast-feeding, while only 30.3% of  Malay and 40.7% of Indian did not ever breast 
feed. 
 
The relative risk of breast cancer among Chinese did not increase with increasing months 
of oral contraceptive use. But it indicated a higher risk of breast cancer in cases of “ever 
used” OC compared with the “never used” group. This was also observed in the Malay 
group. 
 
When we limited the regression to women who had a natural menopause (Table 4.3.3.c), 
the age of menopause did not show any statistically significant difference between control 
women and breast cancer women in the Chinese or Malay groups. But in the Indian group, 
controls’ menopause age (46 years) was significantly younger than breast cancer patients 
(53 years). The adjusted odds ratio was 1.45 (95% C.I. 1.07~1.97, P<0.05). 
 
When we restricted the logistic regression analyses to parous Chinese women, the results 
(See Table 4.3.3.d) indicated that age at first time abortion and number of abortions or 
miscarriages were associated with breast cancer risk in Chinese women (Since so few 
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Malay or Indian women admitted to abortion, no further analysis was carried out in these 
two groups). The results were indicative of a larger relative risk in those who had their 
first time abortion or miscarriage at an older age of greater than 30 years old. The adjusted 
odds ratio was 4.58 (95% C.I. 2.25~9.35) compared with those who never had those 
experiences. In addition, regardless of the age of abortion or miscarriage, there were 
higher risks in the group that experienced one or more times abortion or miscarriages. The 
adjusted odds ratio was 2.54 (95% C.I. 1.60~4.02) compared with those who didn’t.   
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Table 4.3.3 Adjusted odds ratio and 95% confidence intervals for breast cancer by 
female hormonal and reproductive related factors among Chinese, Malay and Indian 
women in Singapore, 2001-2002 
 
Percentage of 
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Take medicine disrupted menarche (oral contraceptive/ estrogen pill/ traditi onal Chinese medicine) (months) 



















0  0 6.5 
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Chinese Malay Indian Menopausal  age (limited to natural 
postmenopause women) Mean age Odds ratio Mean age Odds ratio Mean age Odds ratio 
Control 50.57 1 50.25 1 46.33 1 





*P value less than 0.05 
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Table 4.3.3.d 
Abortion information related with breast cancer (Chinese) 
 
Cases Controls  
N (%) N (%) 
Odds Ratio 
Times of abortion or miscarriage (Married Women only) 
None 88(56.1%) 147(76.6%) 1 
>=1 69(43.9%) 45(23.4%) 2.54* 
(1.60~4.02) 
Age of first time abortion or miscarriage (Married Women only) 
None 88(56.1%) 146(76.0%) 1 
<20y 2(1.3%) 1(0.5%) 3.23 
(0.29~36.16) 
20-30y 33(21.0%) 33(17.2%) 1.67 
(0.96~2.90) 
>=30y 34(21.7%) 12(6.3%) 4.58* (2.25~9.35) 
    
*P value less than 0.05 
Adjusted for age (years), education (years of schooling), marital status (married or not), dwelling (classified 
by types of house), whether own a car, smoking and alcoholic drinking by logistic regression analysis. 
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4.3.4 Anthropometrics in different ethnic groups 
 
Table 4.3.4 compares the anthropometric measurements that of the three ethnic groups in 
our study. Adjusted odds ratio (by age, education, marital status, dwelling, family car 
ownership, smoking and alcoholic drinking) and 95% confidence intervals for Chinese, 
Malay and Indian women were computed. 
 
No differences were seen in the age-adjusted associations with breast cancer among 
Chinese, Malay and Indian women for height at age 18 years. Even through the odds ratio 
of a height greater than 150cm is greater than 1 among three ethnic groups, there was no 
statistically significant relationship between breast cancer risk and taller women in our 
study population. 
 
Surprisingly, we observed an increased risk of breast cancer in the Chinese group when 
the body mass index at age 18 years was less than 18.5kg/m2. The odds ratio is 1.92 (95% 
C.I. 1.23~2.9) (P<0.05). In the Malay and Indian groups, again the sample size was too 
small to study such an effect. In addition, there are no differences in BMI (at 18 years old) 
distributions among the three ethnic groups. These results are surprising and it is difficult 
to reconcile with the hypothesis of body mass index with breast cancer. There are 
probably many other as yet clinical and molecular factors relevant in this group to be 
further investigated. 
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In the Malay and Indian groups, the proportion of heavier body mass index as adults was 
higher in breast cancer patient group than in control group. We found that a current higher 
body mass index was associated with an increased risk of breast cancer among Malay 
women. The odds ratio was 3.9 (95% 1.39~11.2) (P<0.05). It should be noted that the 
number of Malay women in this category was small. However, the percentage of higher 
BMI (more than 25kg/m2 current) in Indian breast cancer patients (63%) is similar as that 
of Malay (60.6%), which is strikingly higher than that of Chinese (27.6%). 
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Table 4.3.4 Adjusted odds ratio and 95% confidence intervals for breast cancer by 
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*P value less than 0.05 
Limit BMI at age 18y to premenopause women and BMI current to postmenopause women. 
Adjusted for age (years), education (years of schooling), marital status (married or not), dwelling (classified 
by types of house), family car ownership, smoking and alcoholic drinking by logistic regression analysis. 
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4.3.5 Family history and benign breast disease history in different ethnic 
groups 
 
The relationship between family history or benign breast disease and breast cancer risk 
among Chinese, Malay and Indian subjects are described in Table 4.3.5, adjusted for 
confounding factors by age, education, marital status, dwelling, family car ownership, 
smoking and alcohol drinking. 
 
A history of benign breast disease was associated with breast cancer risk among all three 
ethnic groups, but the confidence intervals indicated statistical significance only in 
Chinese 5.67 (95% C.I. 2.95~10.91) (P<0.05) and Indian groups 4.03 (95% C.I. 
1.08~14.99) (P<0.01). 
 
Since the number of patients with a positive family history of breast cancer was too small 
to compute, we combined all items of reported family members (excluding spouse or 
spouse’s family) with a past history of cancer. The adjusted odds ratio associated with 
positive family history was 1.78 (95% C.I. 1.16~2.71) (P<0.05) in the Chinese group. 
Although in Malay or Indian groups, there was also a higher odds ratio, the relationship of 
positive family history and breast cancer was not statistically significant. 
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Table 4.3.5 Adjusted odds ratio and 95% confidence intervals for breast cancer by 
female family history and benign breast disease among Chinese, Malay and Indian 
women in Singapore, 2001-2002 
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*P value less than 0.05; 
** P value less than 0.01. 
Adjusted for age (years), education (years of schooling), marital status (married or not), dwelling (classified 
by types of house), family car ownership, smoking and alcoholic drinking by logistic regression analysis. 
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Chapter 5 Discussion and Conclusion 
 
The primary objective of this study was to investigate aspects of breast cancer in 
Singapore. Particularly, our intention was to investigate the ethnic variation of breast 
cancer in Singaporean women in the past three decades and to determine the possible 
reasons for the different pattern of breast cancer among the Chinese, Malay and Indian 
population. We also conducted a hospital-based case-control study matched for ethnic 
group and age to obtain information on known and identified risk factors by personal 
interview. 
 




As the incidence of breast cancer is known to vary among countries or ethnic groups, 
[Kelsey, et al, 1993; Miller, et al, 1986], the present study has shown that ethnic variation 
also exists in Singapore. Different patterns of increase in breast cancer incidence among 
Chinese, Malay and Indian have been shown in the present study.  
 
On the whole, all three ethnic groups show increases in the incidence of breast cancer over 
the past 3 decades. The greatest incidence is in the Chinese group while the highest annual 
increase is shown in the Malay group. There is a strong suggestion of a bimodal 
distribution in age-specific incidence, with the two peaks at 45 and at 65 years seen 
clearly in the Chinese group. In addition, the Indian group has the highest post-
menopausal breast cancer incidence, while the Chinese group has the highest incidence in 
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the pre-menopausal age bracket. The novel observations have not been described 
previously, and these ethnic differences in patterns have not been described in other 
populations previously. 
 
Further analysis of the ethnic differences by plotting the birth cohort incidence rates of 
breast cancer supported and strengthened our hypothesis and observation that there was a 
real increase in the Chinese group, seen increasingly in each birth cohort, that was not 
present in the other two ethnic groups (as yet). The smaller numbers in the Malay group 
may have made a trend less easy to ident ify, but the recent large increase in the most 
recent (youngest) age groups was clear, but this was not seen in the other birth cohorts in 
the Malay group. 
 
 In our case-control study, we demonstrated that late age of marriage and having fewer 
children in Chinese women are two important risk factors of breast cancer. This is 
consistent with the results previous reported by Ng et al in Singapore [Ng, et al, 1997]. 
Compared to the Chinese group, Indian and Malay women tend to marry earlier, have 
children earlier and have more children. We have demonstrated this in our present case-
control study (Section 4.3.3). From our primary results, Indian women have the lower 
incidence rate of breast cancer in the pre-menopause sub-group compared with Chinese 
women. This is consistent with the report of Gajalakshmi, et al [1991], who suggested that 
the protective effect of early full-term pregnancy is probably related to the prevention of 
tumor initiation.  
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In addition, our finding supports the idea that a long duration of lactation reduces breast 
cancer [Newcomb, et al, 1994]. We demonstrated that an increase in the period of breast-
feeding has a protective effect against breast cancer in the Chinese group. These findings 
are similar to many other published studies [Pathak, et al, 1992; Kvale and Hench, 1988]. 
They also are consistent with the previous study in Singapore [Ng, et al, 1997]. One 
unexpected finding is that the percentage of non-breast-feeding in Chinese women is 
much higher than that of Malay and Indian (Section 4.3.3). This also could be one of the 
explanations why young Chinese women have a higher risk than other ethnicities. 
 
We found that the experience of abortion increases the risk of breast cancer, especially in 
the women older than 30 years. Pike suggested that pregnancy precipitates an increase in 
hormone levels, but if this process is artificially interrupted (abortion), the hormone levels 
drop dramatically which renders the breast cells “vulnerable” to carcinogens. Abortion 
related variables were only examined in Chinese women because few Malay and Indian 
women in our subjects had this experience. This may be another reason for the higher 
incidence of breast cancer in Chinese women in Singapore. 
 
Singapore is a multi-racial country with a high proportion of new immigrants. From the 
report of Cancer Incidence in Five Continents [Waterhouse et al, 1993], it was noted that 
there was a higher incidence of breast cancer in Indians (34 per 100,000) compared to 
others in their native counties (Chinese 31.6 per 100,000 and Malay 23.2 per 100,000). In 
Singapore, the varying lifestyles of the three ethnic groups are still retained to some 
extent, especially in the older post-menopausal group of women. This may be a possible 
explanation why Indian women had the highest incidence rate in the postmenopausal 
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women compared to others. In addition, in our case-control study (Section 4.3.4), we 
found that older Indian women have the highest percentage of higher body mass index 
compared with Malay and Chinese women. This could be consistent with the suggestion 
that weight gain in later life is associated positively with risk for breast carcinoma, 
regardless of body mass index in early adulthood [Chu SY, et al, 1991]. 
 
Many studies [Dewaard, et al, 1964; Topper, et al. 1980; Pike, et al, 1983; Russo, et al, 
1995] have suggested that there are a variety of different mechanisms for the etiology of 
breast cancer. One of the theories propounds the view that “Breast tissue age” is an 
important factor of pre-menopausal breast cancer. This is closely related to the age of 
menarche, the age of first term of full pregnancy and the age of menopause. 
Coincidentally, Indian women have the earliest age of all 3 of the above items (Section 
4.3.3). Maybe this is the reason that Indian women have a lower incidence than Chinese 
women in pre-menopausal breast cancer. 
 
Malay women have a lower incidence but a greater annual increase of breast cancer 
compared with Chinese and Indian women. It should be noted that Malay women had the 
lowest incidence rate than others in their native countries [Waterhouse, et al, 1993]. 
Therefore this lower incidence could be related to their different lifestyles, and a host of 
other socio-cultural differences between the races [YIP & Ng, 1996]. In our case-control 
study, we found that the median age at presentation of breast cancer in Malays was 
younger than Chinese and Indian women, and more than half of the patients were 
premenopausal, in contrast to Indian women, whose two-third were postmenopausal. 
Younger Malay women may have experienced greater changes with regard to risk factors 
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[YIP & Ng, 1996] for breast cancer compared with their older generation, which may 
have led to the average annual change increase. A finding in our case-control study was 
that OC (Oral Contraceptive) use increased the risk in Malay women (Section 4.3.3) and 
this risk was even higher than in their Chinese counterparts. Many other studies have 
shown that Oral contraceptive use increases the risk of breast cancer [Spicer, et al 1994; 
Palmer, et al 1995; Brinton, et al 1997]. However, since many lifestyle related factors, 
such as diet, working stress, exercise were not investigated in our case-control study, we 
cannot give further suggestions why Malay women had the greatest annual increase in this 
study. 
 
In our case-control study, the results indicate that Chinese, Malay and Indian women 
shared a common subset of some risk factors for breast cancer but that other subsets of 
factors related to breast cancer were distinguishable between the three ethnic groups. 
Cycle length of menses period, menopause status, age at first marriage, number of full 
term pregnancies, age at first pregnancy and oral contraceptive use, were in the subset of 
distinguishable factors related to breast cancer risk among Chinese, Malay and Indian 
women in Singapore. These may help to provide an explanation for different patterns for 
incidence rates of breast cancer. Although our study has focused on hormone related 
factors, the effect of hormonal factors may be mediated by dietary intake [Maclure M, et 
al, 1991], genetic factors and other factors [Fries H, et al 1974]. The prevalence of these 
factors also varies by ethnicity [Maclure M, et al, 1991]. 
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5.2 Validity of the results 
 
5.2.1 Validity and reliability data of the primary study 
 
The findings observed in our primary study are likely to be reliable and real due to the 
following reasons. 
 
The information notified to the Singapore Cancer Registry shows a high level of 
reliability. Up to 89.7% of total breast cancer cases for females were confirmed by 
histopathological reports in the period from 1968 to 1997, the remainder being diagnosed 
by clinical, radiological or other examinations. Our validation study demonstrated the 
accuracy of demographic data obtained. Moreover, the definitions of disease were 
consistent throughout this study and coding practice has not been changed over time. 
 
We believe that referral patterns are not a problem here since the study was population-
based and all diagnosed cases were included between 1968 and 1997. The registry 
receives notifications from all medical practitioners and quality control checks through all 
histopathological reports and hospital discharge summaries (Chia et al, 1996 & 2000). In 
this way, close to complete case ascertainment is ensured, as Singapore is a small island 
country with good communication links. 
 
5.2.2 Quality of the data in the case-control study 
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The strong point of the present case-control study is the inclusion of only 
histopathologically confirmed cases of breast cancer. We excluded non-primary sites that 
manifested as breast cancer, through a careful review of the medical records of all cases.  
 
The study population had the added advantage of being relatively homogeneous in that all 
the patients and controls had lived in Singapore for more than five years. This allowed us 
to examine the exposure of interest without the confounding effects of factors associated 
with these attributes. As the denominators of Malay and Indian populations are lower in 
Singapore [Lau, 1992], we faced difficulty in interpreting the risk estimates among Malay 
and Indian because of the much smaller numbers involved. Comparatively, the large 
number of Chinese in our study population allowed us to estimate fairly precisely the odds 
ratios for this group.  
 
All interviews were conducted in-person by the same interviewer. Thus the uncertainty 
associated with proxy interviews was avoided. The potential for interviewer bias in which 
knowledge of the patient’s disease status may influence the intensity of the search for the 
putative cause, exists in all case-control studies. In order to avoid that, we tried to clearly 
define the questionnaire items before patients were interviewed. On the other hand, 
differential recall of exposure between cases and controls should also be considered; this 
is usually more problematic when community controls are used [Henneken and Buring, 
1996], which is not the case in the present study. Further, in introducing the study to 
eligible participants, the general term “women’s health” was used and not “breast cancer”. 
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We also gathered information from cases and controls concurrently. Controls were 
matched to cases on age at admission +5 years. We chose to use hospital, rather than 
population controls, the reasons for this choice be ing primarily concern that participation 
rate in the community would not be high. Whereas the use of hospital controls is 
considered by some to be less desirable than population controls, in a disease like breast 
cancer, this is likely to be less important than diseases which are more chronic and which 
receive more community care. 
 
From our arguments above, we therefore believe that the quality of the data in the present 




5.3 Conclusions  
 
 We conclude that 
1. In Singapore, the three main ethnic groups, Chinese, Malay and Indian have all 
had strikingly significant increases in incidence of breast cancer over the past 3 
decades. 
2.  The changes in incidence rates of breast cancer in three ethnic groups have 
different patterns.  
· The greatest incidence rate is in the Chinese group while the highest annual 
increase is in the Malay group.  
Part I    - 85 - 
· The Indian group has the highest post-menopausal breast cancer incidence, 
while Chinese group has the highest incidence in pre-menopausal breast 
cancer. 
3. The case-control study indicated that certain identified hormonal related risk 
factors might differ by ethnic groups. 
4. There are some limitations in our case-control study:  
· The variances of the relative risk estimates are greater for Malay and Indian 
women because of the smaller sample size.  
· Some other risk factors, such as dietary intake, immigration, genetic factors, 
which are indirectly related with hormonal factors, have not been studied.  
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Chapter 6 Introduction 
 
 
Several studies have shown an association between body mass index and breast cancer 
(See Part I). As body mass index is an indirect measure of body fat, there are some 
suggestions that the relation of breast cancer and body mass index is primarily because of 
body fat. One of the possible mechanisms may be via estrogen excess in breast tissue, due 
to direct peripheral androgen aromatization in fat tissue.  
 
Recently, human leptin has been discovered and been described to be produced by adipose 
tissue. While the main function of the leptin is thought to be involved in the control of 
body fat by the regulation of energy homeostasis, other roles have been investigated also. 
For example, it is now thought that leptin might play an important role in reproduction 
and during gestation [Butte, et al, 1997]. 
 
Leptin is produced in adipose tissue [Zhang, et al, 1994] and this protein is a 167 amino 
acid protein transcribed from the obesity gene. Leptin achieves most of its metabolic 
effects by interacting with its specific receptor [Campfield, et al, 1995]. The leptin 
receptor is a member of the class I cytokine receptor family, a family that also includes 
the interferon receptor, growth hormone receptor and interleukin-2 receptor. The leptin 
receptor has been identified and described in many human tissues, such as ovarian cell, 
hepatic cell, pancreatic ß-cell and others. Evidence also showed that the leptin receptor 
and its mRNA are present in ovarian tissue of rodent and human. Whereas the leptin 
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receptor has been described in human breast tissue, it has not been investigated much 
more. 
 
Generally, leptin reflects the amount of energy stores that regulates energy balance and is 
associated with circulating levels of reproductive hormones. Breast cancer has also been 
associated with obesity, reproductive hormones and circulating. To investigate whether 
leptin is related with proliferation of breast cancer, the effect of exogenous leptin on the 
breast cancer cell line, MCF-7 was studied in vitro. Furthermore, cDNA microarray was 
used to investigate the effect of leptin on breast cancer. 
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Chapter 7 Literature review 
 
7.1 Leptin  
 
In 1994, the obesity gene was cloned and its encoded 167 amino acid (novel leptin) was 
identified. [Zhang, et al, 1994]. The mature polypeptide is a 16-kDa adipocyte secreted 
molecule found in the blood of multiple mammalian species including mice and humans 
[Maffei, et al, 1995]. Although the primary amino acid sequence of leptin appeared 
unrelated to any known proteins, threading analysis performed to gauge tertiary structure 
suggested leptin would fold into a helical cytokine -like structure similar to interleukin-2 
(IL-2) and growth hormone (GH)[Madej, et al, 1995]. 
 
Leptin expression has been shown to respond to a variety of stimuli including 
glucocorticoids, cytokines and insulin [Saladin, et al, 1996; Grunfeld, et al, 1996; Slieker, 
et al, 1996]. More importantly, the steady-state levels of leptin mRNA and its protein 
product are elevated in a variety of animal obesity models and appear to correlate with 
the percentage of body fat [Maffei, et al, 1995; Frederich, et al, 1995; Frederich, et al, 
1995]. These findings have fostered the idea that leptin serves as an “adipostat”, 
informing the body of the available energy stored in the adipose tissue. 
 
Leptin mRNA and protein is also regulated in humans by both changes in percentage 
body fat as well as acute changes in food intake. Expression is upregulated in individuals 
with increased body fat and is down-regulated during body weight reduction [Considine, 
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et al, 1996; Hamilton, et al, 1995; Lonnqvist, et al, 1995].The administration of 
recombinant leptin to rodents results in food intake reduction and weight loss[Campfield, 
et al, 1995; Halaas, et al, 1995; Pelleymounter, et al, 1995; Stephens, et al, 1995]. A 
recessive mutation in the ob gene caused severe hereditary obesity in the ob/ob mouse, 
while the injection of exogenous leptin protein reversed the obesity [Sinha, et al, 1997].  
 
 
7.2 Biologic effects of leptin 
 
Initial models of leptin action included ob/ob mice, which are leptin deficient, and db/db 
mice, which are leptin insensitive due to a receptor defect. Peripheral or central 
administration of leptin reduced the body weight, adiposity and food intake of ob/ob mice 
but not of db/db mice [Campfield, et al, 1995; Pelleymounter, et al, 1995]. The 
behavioral effects after administration to the brain suggests that leptin can act directly on 
neuronal networks, which control food intake and energy balance [Campfield, et al, 
1995; Cusin, et al, 1995; Hamann, et al, 1996]. It has been shown that leptin acts by both 
suppressing food intake and by stimulating energy expenditure, including thermogenesis 
[Campfield, et al, 1995; Halaas, et al, 1995].  
 
Leptin suppresses NPY (neuropeptide Y system) expression and secretion in the arcuate 
nucleus. NPY is a strong stimulator of food intake and is involved in the regulation of 
various pituitary hormones. Leptin decreases food intake through inhibition of NPY 
mRNA expression, which in turn can cause a decrease in insulin levels. Low insulin 
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levels on the other hand cause a down regulation of leptin [Tomaszuk, et al, 1996; 
Stephens, et al, 1995; Spitzweg and Heufelder, 1997].  
 
In addition to its effect on energy balance, leptin is also important for normal progression 
of pregnancy and for female reproduction and sexual development. Leptin corrects the 
infertility in the ob/ob mouse possibly by directly influencing the GnRH-LH/FSH axis 
[Chehab, et al, 1996]. It has been postulated that leptin stimulates the production of 
reproductive hormones. Subjects with a low body fat mass have disrupted reproductive 
systems, as do people who are starving. Women stop ovulating and testosterone levels 
decline in men [Kopp, et al, 1997]. Leptin may well be one of hormonal factors which 
signal to the brain at what time the body is ready for sexual maturation and reproduction. 
[Lahlou, et al, 1997]. 
 
Leptin levels in maternal serum are high throughout pregnancy [Butte, et al, 1997]. 
During late pregnancy and at birth when maternal fat stores are developed and leptin 
levels are high, leptin could be an important signal to the brain, signaling the status of 
satiety and expansion of fat stores. Also, high levels of leptin might lead to uncoupling of 
eating behavior, to the filling up of fat stores and to a relative unresponsiveness of leptin 
receptors during late gestation. Teleologically, it would make sense to prepare additional 
energy stores for the stress of birth and allowing for adequate lactation afterwards 
[Gluckman, et al, 1996]. 
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7.3 Leptin receptor and signal transduction 
 
Leptin acts through interactions with specific receptors [Campfield, et al, 1995]. The 
leptin receptor (Ob-R) is a large single membrane spanning protein and belongs to the 
cytokine class I receptor family [Tartaglia, et al, 1995]. Class I cytokine receptors contain 
highly conserved Box 1 and Box 2 motifs proximal to the transmembrane domain 
[Murakami, et al, 1991]. Box motifs mediate the association of Janus -activated kinase 
(JAK) family members with cytokine receptors, allowing the cytokine receptor to initiate 
an intracellular signaling cascade. While membrane-bound leptin receptor isoforms 
contain a Box 1 motif, only the long form of the receptor (OB-Rb) isoform contains an 
additional Box 2 motif. The OB-Rb isoform is also the only leptin receptor that contains 
intracellular tyrosine residues, which upon phosphorylation, allows interaction with 
specific signaling proteins [Tartaglia, et al, 1995and Tartaglia, et al, 1997]. Whereas 
signaling of the leptin receptor is similar to interleukin 6 (IL-6)-type cytokine receptor 
signaling, activation of OB-Rb is independent of the signal transducing subunit gp130, 
which is necessary for activation of the IL-6 receptor [Tartaglia, et al, 1995; Baumann, et 
al, 1996; White, et al, 1997]. Instead, leptin receptor signaling appears to be initiated by 
ligand-induced receptor homo-dimerization [White, et al, 1997].  
 
A considerable amount of work has been performed to elucidate the intracellular 
signaling pathway regulated by leptin. This work has implicated JAK family members, 
signal transducers and activators of transcription (STAT), as well as mitogen-activated 
protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways in leptin 
receptor-mediated signal transduction [Baumann, et al, 1996; Bjørbæk, et al, 1997; 
Part II    - 92 - 
 
Banks, et al, 2000; Rosenblum, et al, 1996; Yamashita, et al, 1998; Ghilardi, et al, 1996]. 
(See Figure 7.3.1) Transfection studies have demonstrated that ligand binding to OB-Rb 
results in activation of the JAK/STAT signaling pathway, whereas cells transfected with 
OB-Ra did not display leptin-induced JAK/STAT activation [Ghilardi and Skoda, 1997]. 
Furthermore, administration of leptin to female ob/ob and wild type mice activates 
hypothalamic STAT3. In contrast, db/db mice, which have a truncated OB-Rb, fail to 
exhibit an increase in STAT3 activation, implicating the OB-Rb isoform in mediating the 
biologic effects of leptin, in vivo [Vaisse, et al, 1998]. The inability of leptin to induce 
STAT3 activation in db/db mice appears to be due to the fact that db/db mice lack a 
YXXQ motif in the cytoplasmic tail of the OB-Rb, which represents a consensus STAT3 
binding motif [Tartaglia, et al, 1995]. Finally, recent research by several groups has 
implicated the nuclear transcription factors c-fos, c-jun and egr-1 as being regulated by 
leptin and potentially participating in leptin signaling [Murakami, et, al, 1997; Uotani, et 
al, 1994]. Further work is needed before a precise understanding of the contribution of 
these factors to leptin signaling can be reached. Nevertheless, as a whole, the above 
findings suggest STAT3 regulation of target genes plays an important mediator role in 
leptin signaling, which appears to be critical to the ability of leptin to regulate food intake 
and energy metabolism in vivo.  
 
While the pathways responsible for mediating the actions of leptin have received 
considerable attention, less is known about the mechanisms that limit leptin signaling. 
Recent studies on this issue have demonstrated that STAT3 induces gene transcription of 
the suppressor of cytokine signaling-3 (SOCS-3) [Bjørbæk, et al, 1998]. The SOCS 
family of proteins consists of eight members, each of which contains a Src-homology 
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(SH2) domain and a C-terminal SOCS box [Starr, et al, 1997]. SOCS proteins are 
induced by a wide variety of cytokines and function to inhibit cytokine-mediated signal 
transduction, thus serving a negative feedback role. Recent work demonstrated that 
overexpression of SOCS-3 results in the inhibition of leptin-induced tyrosine 
phosphorylation of JAK2, thus preventing the activation of the JAK/STAT pathway 
following the addition of leptin [Bjørbæk, et al, 1999]. Subsequent studies determined 
SOCS-3 also inhibits leptin signaling by binding to phosphorylated Tyr-985 on the leptin 
receptor, thereby blocking the interaction of this residue with SH2-containing 
phosphatase (SHP-2), a tyrosine phosphatase [Bjørbæk, et al, 2000; Li and Friedman, 
1999]. SHP-2 is ubiquitously expressed and generally acts to positively regulate cytokine 
signaling. Following cytokine receptor stimulation, SHP-2 becomes tyrosine 
phosphorylated and acts as an adaptor molecule to recruit Grb2 and Sos, members of the 
Ras/MAPK/ERK signaling pathway. Using a dominant negative SHP-2 construct, 
Bjørbæk et al. demonstrated SHP-2 is essential for leptin-induced MAPK 
phosphoyrlation by OB-Rb [Bjørbæk, et al, 2000]. In contrast, a recent study reported 
that SHP-2 acts as a negative regulator of OB-Rb signaling by inhibiting STAT3 
mediated transcription [Carpenter, et al, 1998]. Thus, the precise role of SHP-2 in leptin 
signaling has not been completely resolved.  
 
Nevertheless, based on the studies described above, it can be concluded that leptin 
signaling involves mediator roles for the JAK/STAT and MAPK/ERK pathways, and that 
SOCS3 may serve to limit/restrain leptin action. These intracellular signaling pathways 
suggest some overlap with those of other growth factors, and of Growth Hormone in 
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particular [Kaulsay, et al, 2000]. The presence of these overlapping signaling pathways 
may indicate a possible involvement of leptin in breast cancer. 
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Leptin receptor signaling is initiated by the binding of leptin to the extracellular domain of the OB-Rb 
dimer. Jak 2 binds to Box 1 and Box 2 motifs on the receptor, leading to Jak 2 transphosphorylation and 
activation. Activated Jak 2 subsequently phosphorylates Tyr985 and Tyr1138 of the leptin receptor. 
Phosphorylated Tyr985 and Tyr1138 immediately bind SHP-2 and STAT-3, respectively, which are then 
phosphorylated by Jak 2. Tyrosine-phosphorylated SHP-2 binds GRB-2, resulting in the activation of the 
Ras/Raf MAPK/ERK pathway. GRB-2 may potentially also be activated directly by Jak 2. Activated 
MAP/ERK translocates to the nucleus, where it induces transcription of immediate early response genes 
such as c-fos, c-jun, and B-jun, as well as egr-1. Tyrosine-phosphorylated STAT-3 dimerizes and 
translocates to the nucleus, where it induces transcription of STAT-3-responsive genes, including SOCS3. 
After socs3 mRNA has been translated and translocated to the cytoplasm, SOCS3 binds to phosphorylated 
Tyr985 and blocks the SHP-2/MAPK/ERK pathway and may also bind Jak 2 directly to negatively regulate 
leptin receptor signaling. 
Sourc:Brann, et al, 2002 
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Chapter 8 Materials and Methods 
 
MCF-7 cells were cultured at 37oC in 5% CO2 in RPMI supplemented with 10% heat-
inactivated FBS, 100U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. 
 
8.1 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
analysis.  
 
Total cellular RNA was extracted from MCF-7 cells by the RNeasy Mini Kit (QIAGEN). 
According to the protocol (QIAGEN OneStep PCR Kit), 5x OneStep RT-PCR buffer, 
DNTP mix, 5x Q-solution and RT-PCR Enzyme Mix were prepared for a master mix. 
cDNA was synthesized from 1µg of total RNA. For amplification of the cDNA products, 
human leptin receptor specific primers (Primer 1:sense primer, 5- tgttgtgaatgtcttgtgcc-3 
and anti sense primer 5-cattagacccaacacttgtc-3 or Primer 2:sense primer, 5-
tgttgtgaatgtcttgtgcc-3 and anti sense primer 5-tggaaatggtaccaatggtg –3) were added in the 
individual PCR tubes. PCR was performed on the Gene Amp PCR system 9600 .The 
details of thermal cycles are following: Reverse transcription 50oC for 30min, Initial PCR 
activation step 95oC for 15min, 3-step cycling for 35 circles and Final extension at 72oC 
for 10min. Each cycle was carried out 30s denaturation step at 94oC, 30s annealing step 
at 52oC and extension at 70oC .PCR products were separated on a 1.5% agarose gel and 
stained with ethidium bromide. 
 
8.2 Western blot analysis 
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MCF-7 cells were washed once in ice-cold PBS and scraped into 1 ml of 1x lysis buffer 
[2x lysis buffer: 2% Triton X-100, 20mM Tris-HCl, pH 7.4, 300 mM NaCl, 2mM EDTA, 
2mM EGTA, 0.4mM Na3VO4, 1% Nonidet P-40, 0.1% phenylmethylsulfonyl fluoride 
(PMSF)]. Lysate was incubated on ice for 15 min and then centrifuged for 20 min at 4oC 
and 12,500 x g, and the supernatant was collected. Protein concentration was determined 
in triplicate by the Bro-Rad protein assay using bovine serum albumin (BSA) as the 
standard. Protein was resuspended in 2x SDS-sample buffer (50mM Tris, pH 6.8, 2% 
SDS, 2% ß-mercaptoethanol, and bromophenol blue), boiled for 10 min, and centrifuged 
at 14,000 x g for 2 min. Protein was separated by 7% SDS-PAGE [1.5M Tris -HCl, pH 
8.8, 20% (w/v) SDS, acrylamide/bisacrylamide (30%/0.8% w/v), 10% (w/v) ammonium 
persulfate, 0.05%TEMED] in 1xLaemlli running buffer [5x Laemlli running buffer: 
120mM Tris (hydroxymethyl) methylamine, 960 mM glycine, 17mM sodium dodecyl 
sulfate (SDS)], transferred to a nitrocellulose membrane using a semidry apparatus in 
Laemlli buffer [23mM Tris (hydroxymethyl) methylamine, 19mM glycine, 0.64 mM 
SDS] containing 10% methanol. Subsequently, membrane was blocked with 5% skim 
milk in PBS with 0.1% Tween 20 (PBST) for 1h at room temperature and then washed 
twice for 5 min each in PBST.  Immunoblotting of the membrane with monoclonal 
antibody against leptin receptor (1:1000) was performed for 1h at 22 oC with 1 x PBST 
containing 1% skim milk powder. After six washes for 10 min each in PBST, the 
membrane was incubated with anti-rabbit HRP (1:10,000) (Amersham, Corp.) in PBST 
containing 1% skim milk powder for 1h at 22oC. The membrane was further washed six 
times for 10 min each in PBST, and revealed using the enhanced chemiluminescence 
(ECL) system.  
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8.3 Confocal Laser Scanning Microscopy for leptin receptor  
 
MCF-7 cells were cultured on glass coverslips, fixed in ice-cold 4% paraformaldehyde 
(in 1 x PBS pH 7.4), washed in 1 x PBS, permeabilized for 10 min with 0.1% Triton X-
100 (in 1 x PBS), blocked for 1 h at 22oC in 1 x PBS containing 2% BSA, and incubated 
with either a monoclonal antibody against Leptin receptor (dilution 1:150) or with Rabbit 
anti-mouse serum (dilution 1:150) in incubation buffer (1 x PBS, pH 7.4, 1% BSA). For 
detection, FITC (1:150) and phalloidin-TRITC (1:1000) labeled goat anti-rabbit diluted 
in incubation buffer (1% BSA/PBS, pH 7.4)) was used at 22oC. After 5 washes in PBS 
the coverslips were mounted and labeled cells visualized with a Carl Zeiss Axioplan 
microscope equipped with epifluorescence optics and a Bio-Rad, Inc., MRC1024 
confocal optics system. Images were converted to the tagged information file format 
(TIFF) and processed with the Adobe Photoshop program.  
 
8.4 Cell proliferation assay using 5-Bromo-2’-deoxyuridine (BrdU) 
staining 
 
Mitogenesis was directly assayed by incorporation of 5-Bromo-2’-deoxyuridine (BrdU) 
during DNA synthesis (Sawa et al., 1999). MCF-7 cells were cultured on the glass 
coverslips to 25% confluence in six-well plates. Cells were washed twice with PBS 
before being serum deprived for 12 hours. Cells were treated in either serum-free RPMI 
medium or serum free medium supplemented with 100nM leptin or serum free medium 
supplemented with 10nM U0126 or serum medium supplemented with 10nM U0126 then 
treated with100nM leptin. 24 hours later, all cells were pulse-labeled with 20 mM BrdU 
(Sigma) for 30 min, washed twice with PBS, and fixed in cold 70% ethanol for 30 
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minutes. BrdU detection was performed by using the BrdU staining Kit (Zymed, South 
San Francisco, CA) according to the manufacturer’s instructions, A total population of 
over 400 cells was analyzed in several arbitrarily chosen microscopic fields to determine 
the BrdU labeling index (percentage of cells synthesizing DNA). 
 
8.5 Mitogen-activated protein (MAP) kinase activity in MCF-7 cells 
 
MAP kinase activity was measured with the p44/42 MAP Kinase Assay kit (Cell 
Signaling Technology Catalog #9800), according to the manufactures recommended 
protocols. 
8.5.1 Immunoprecipitation of proteins from cell extracts 
 
MCF-7 cells were grown to 50% confluence in 10% serum-supplemented medium, 
incubated for 12 hours in serum-free medium and stimulated by indicated dose leptin for 
15minutes (for Dose-response experiments) or by 100nM leptin for indicated time 
periods (for Time course experiments). Cells were washed with ice-cold PBS and lysed 
with 1ml of lysis buffer [20mM Tris (pH7.5), 150 mM NaCl, 1mM EDTA, 1mM EGTA, 
1% Triton X-100, 2.5 mM sodium pyrophosphate, 1mM ß-Glycerolphosphate, 1mM 
Na3VO4, 1µg/ml Leupeptin, 1mM PMSF]. After micro-centrifugation for 20min at 4oC, 
the supernatant was subjected to immunoprecipitation using the Phospho- 44/42 MAPK 
(Thr202/Tyr204) monoclonal antibody with agarose beads. After overnight agitating at 
4oC, micro-centrifuge for 30 seconds at 4oC, washing pellet twice with ice-cold lysis 
buffer, then washing with ice-cold kinase buffer [25mM Tris(pH 7.5), 5mM ß-
Glycerolphosphate, 2mM DTT, 0.1 mM Na3VO4, 10mM MgCl2], the pellets were 
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incubated for 30 min at 30oC with the kinase buffer containing 200µM ATP and 2 µg 
Elk-1 fusion protein. The reaction was stopped by the addition of 25µl 3x SDS sample 
buffer and then 30µl of each sample loaded on SDS-polyacreylamide gel electrophoresis 
(PAGE). Proteins were transferred to nitrocellulose membranes using a standard semi-
dry electroblotting apparatus in Laemlli buffer containing 10% methanol. 
8.5.2 Western Blot Analysis  
 
Nitrocellulose membranes were blocked with 5% bovine serum albumin (BSA) in 
phosphate-buffered saline with 0.1% Tween 20 (PBST) for 1 hour at 22oC. Blots were 
then immunolabelled for 1 h at 22oC with rabbit phosphor-specific Elk1 (Ser383) 
antibody (1:1000). After 6 washes for 10 min each in PBST, membranes were incubated 
in horseradish peroxidase-conjugated anti-rabbit for 1 h at 22oC, which were diluted with 
the buffer [20mM Tris (pH7.5), 150 mM sodium chloride, 5% skim milk, 0.1% Tween 
20]. Membranes were further washed six times for 10 min each in PBST before 
immunolabelling detected by ECL according to the manufacturer’s instructions.  
 
8.6 cDNA Array Hybridization Studies 
 
8.6.1 Preparation of Total RNA 
 
Total RNA was isolated from MCF-7 cell lines and MCF-7 cells treated with 200nM 
leptin separately, using the TRI REAGENT method (MOLECULAR research center, inc) 
according to manufacturer's instructions and resuspended in diethyl pyrocarbonate-
treated water. Quantification and purity of the RNA was assessed by A260/A280 
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absorption, and RNA quality was assessed by agarose gel electrophoresis. RNA samples 
with ratios greater than 1.6 were stored at 70°C for further analysis.  
8.6.2 Analysis of Differential Gene Expression by Use of cDNA Microarray 
 
The Atlas cDNA Expression Arrays (C lontech Laboratories, Palo Alto, CA) containing 
588 genes were used in these studies. Poly(A)+ RNA samples from the respective cell 
lines were isolated from total RNA using streptavidin magnetic beads. Following the 
manufacturer’s instructions, Moloney mur ine leukemia virus reverse transcriptase was 
incubated with Poly(A)+ RNA in the presence of [a -32P]dATP for generation of 
radiolabeled cDNA probes. Before labeling for hybridization to the cDNA microarray, 
the radiolabeled cDNA probes were purified from the unincorporated nucleotides by gel 
filtration in chromatography-spin 200 columns. The product was then hybridized to the 
cDNA microarray overnight. After a series of high stringency washes (three 20-min 
washes in 2× saline/sodium citrate (SSC), 1% SDS followed by two 20-min washes in 
0.1× SSC, 0.5% SDS), at 68 °C the membranes were exposed to x-ray film and subject to 
autoradiography. The relative levels of gene expression were quantified by densitometric  
scanning by the use of the GS-700 imaging densitometer from Bio-Rad according to the 
manufacturer's instructions. Genes were considered differentially expressed when they 
exhibited a 2-fold or greater increase or decrease in the presence of leptin (MCF-7 cells) 
compared with the absence of leptin (MCF-7 cells) in three independently performed 
experiments. The relative expression of housekeeping genes (ubiquitin, phospholipase 
A2, glyceraldehyde-3-phosphate dehydrogenase, -actin, -tubulin, 23-kDa highly basic 
protein, ribosomal protein S9) did not differ by more than 10% between MCF-7 cells with 
or without leptin. 




All experiments were repeated at least three, usually five times. All numerical data are 
expressed as mean +S.D. Data was analyzed using the two-tailed t test or analysis of 
variance. 
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Chapter 9 Results 
 
9.1 Expression of the leptin receptor in MCF-7 cell line 
 
To demonstrate the presence of leptin receptor in MCF-7 cells, semiquantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR) was used to display the presence of 
leptin receptor mRNA transcripts in MCF-7 cells.  Using two different primer sets and 
different primer doses, amplified fragments of the predicted size (446bp and 222bp) 
appropriate for the leptin receptor mRNA fragment were detected in total RNA extracts 
from MCF-7 cells. (Figure 9.1.1) 
 
Leptin receptor protein expression was also shown by Western blot analysis. OB-Rb 
protein was detected at 230 kDa by using monoclonal antibody against leptin receptor 
(Figure 9.1.2).  Leptin receptor protein localization within the MCF-7 cell was also 
demonstrated by cofocal Laser scanning microscopy (Figure9.1.3) with the use of a 
monoclonal rabbit leptin receptor antibody. For control purpose, another treatment was 
performed with MCF-7 cells by using rabbit anti-mouse serum for primary antibody. 
Both of them were detected with FITC and phalloidin-TRITC labeled goat anti-rabbit 
(second antibody). Leptin receptor immunoreactivity was detected in MCF-7 cells 
(Figure9.1.3c). No immunofluorescence was detected if antibody against leptin receptor 
was substituted with a monoclonal antibody directed against a species-specific epitope on 
the rabbit leptin receptor (Figure9.1.3a). As positive control, filamentous actin within 
both of the cells was visualized with TRITC-labeled phalloidin (Figure9.1.3b & 
Figure9.1.3 d).  
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Thus, we provide clear evidence for both leptin receptor mRNA and protein expression in 
the human breast carcinoma cell line, MCF-7, in vitro. 
 
 
Figure 9.1.1 Expression of the human leptin receptors mRNA in MCF-7 cell line. 
 
    
Primer1                 0.6uM                       1.0uM   
 











               0.6uM                     1.0uM 
  
 





     
 
 
Reverse transcriptase-polymerase chain reaction demonstration of leptin receptor gene expression in MCF-7 
cells. RT -PCR was performed as described under Materials and Methods to yield a product of 446 bp and 
222 bp. Agarose gel electrophoresis of the amplified fragments from MCF-7 visualized with ethidium 








Figure 9.1.2 Western blot analysis of the human leptin receptor protein expression in 

















Western blot analyses were performed as described under Materials and Methods. OB-Rb protein was 
probed by corresponding antibody and visualized by enhanced chemiluminescence. A single band for OB-
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Figure9.1.3 Leptin receptor demonstrated in MCF-7 cells by cofocal laser scanning 
 
   
 
 
Leptin receptor was detected with the monoclonal antibody against Leptin receptor and confocal laser 
scanning microscopy. a, Lack of immunoreactivity in MCF-7 cells (detected with FITC-labeled second 
antibody); b, Positive filamentous actin control (visualized with TRITC-labeled phalloidin); c, Anti-leptin 
receptor immunoreactivity in MCF-7 cells (detected with FITC-labeled second antibody); d, Positive 
filamentous actin control (visualized with TRITC-labeled phalloidin).  
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9.2 Activation of MAPKinases pathway by leptin in MCF-7 cells 
 
Previous studies have shown that leptin induced cell proliferation acts via the activation of 
the MAPKs pathway [Takahashi et al., 1997, Tanabe et al., 1997 and Tartaglia et al., 
1995]. We measured MAPK phosphorylation after leptin stimulation in the MCF-7 cell 
line. As shown in Figure 9.2.1a, leptin stimulates phosphorylation of Elk-1, which is the 
p44/42 MAP kinase dependent transcription factor. We demonstrated that leptin activated 
MAPK pathway on MCF-7 in a dose-dependent manner. As shown in Figure 9.2.1b, we 
used concentrations of leptin 0, 1, 5, 50 and 100nM at a time duration of 15min. It was 
demonstrated that leptin stimulates phosphorylation Elk-1 with a maximal activation at 
100nM. 
 
 We also used an optimal concentration of leptin (100 ng/ml), during various times of 
stimulation (0, 2, 5, 15, 30, 60 min). In the time-dependent manner, a maximal activation 
was detected at 15 min time point; at longer time duration, this activation diminishes. 
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Figure 9.2.1 Dose and Time dependence of the leptin-stimulated phosphorylation of 
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For dose dependence experiments, MCF-7 cells were stimulated with the indicated concentration of leptin 
for 15 min. For time course experiments, MCF-7 cells were stimulated with 100nM leptin for the indicated 
times. The data presented are representative of at least three separate experiments. 
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9.3 Leptin effect on cell proliferation in breast cancer cell line (MCF-7) 
 
To study the functional role of the leptin receptors on human breast cancer, we evaluated 
the effects of leptin on MCF-7 cell line proliferation by BrdU incorporation assay. We 
demonstrated that leptin induces proliferation of the human breast cancer cell line MCF-7 
in a dose-dependent manner with a maximal activation at 100 nM previously. The BrdU 
incorporation in MCF-7 cells was significantly increased with 100nM leptin (See Figure 
9.3.1 & Figure 9.3.2) 
 
In order to determine if the MAPKs pathways activation is truly involved in leptin-
induced proliferation of MCF-7 human breast cancer cell line, we studied the effect of the 
specific MAPK-inhibitor U0126 on the growth of MCF-7 induced by leptin. MCF-7 cell 
proliferation was inhibited when U0126 specifically inhibited the activation of the 
MAPkinase pathway by (See Figure 9.3.2c and Figure 9.3.2d). Thus, we demonstrated 
that this specific inhibitor, at a concentration of 10 nM, totally inhibits the leptin-induced 
cell proliferation. 
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Figure 9.3.1 Leptin-induced proliferation in p44/42 MAP kinase pathway in MCF-7 



























































Cell proliferation assays were performed as described in Material and Methods. Results represent 
means + SD of triplicate determinations. Results presented are representative of at least three 
independent experiments.  **, P<0.01; NS: No Significance. 
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Figure 9.3.2  Leptin-induced proliferation in p44/42 MAP kinase pathway in MCF-7 









































Cell proliferation was estimated by the BrdU incorporation assay. Microscopy was performed as 
described in Material and Methods. a, MCF-7 cells in serum-free medium; b, MCF-7 cells 
stimulated with 100nM leptin; c, MCF-7 cells treated with 10nM U0126; d, MCF-7 cells treated 
with 10nM U0126 then stimulated with 100nM leptin. The results were shown from three 
independent experiments.  
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9.4 Microarray analysis 
 
To identify genes regulated by human recombinant leptin in MCF-7 cells line, we 
screened a high-density cDNA array with labeled cDNA derived from either serum-free 
MCF-7 cells or stimulated with 200nM leptin for 6 hours MCF-7 cells. Of 588 screened 
genes, 23 exhibited a 2-fold or greater increase in their expression in the presence of 
human recombinant leptin (range 2~7.3 fold) compared with the absence of leptin (See 
Figure9.4.1a and Table 9.4.1). Most of the up-regulated genes were to be found among 
those grouped as oncogenes/tumor suppressors/ cell cycle control proteins; in particular, 
the dramatic effects of leptin up-regulations expression were on Cyclin-dependent kinase 
(CDK1), Mitogen-activated protein kinase 3 (MAP kinase 3; MAPK 3; PRKM3); 
Mitogen-activated protein kinase 3; Type ll cytoskeletal 2 epidermal keratin. Other up-
regulated genes of particular interest include DNA topoisomerase l (TOP1).  
 
17 genes exhibited a 2-fold or greater decrease in their expression in the presence of 
human recombinant leptin (range 2~5.6 fold) compared with the absence of leptin 
treatment (Figure9.4.1 and Table 9.4.2). Most of the down-regulated genes were to be 
found among   DNA binding/ cell cycle control proteins / transcription factors group. The 
effects of leptin down-regulations expression were on purine -rich single-stranded DNA-
binding protein alpha (PUR-alpha), cyclin-dependent kinase 4 inhibitor (CDK4I), 
Interleukin 10 (IL10) and others. 
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The relative expression of housekeeping genes (ubiquitin, phospholipase A2, 
glyceraldehyde-3-phosphate dehydrogenase, -actin, -tubulin, 23-kDa highly basic protein, 
ribosomal protein S9) did not differ by more than 10% between serum-free MCF-7 cells 
and leptin treated MCF-7 cells. 
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Figure 9.4.1 Effect of human recombinant leptin on relative levels of gene expression 
in MCF-7 cells 
 





















cDNA microarray analysis of the relative levels of gene expression in MCF-7 cells. Fig 9.4.1a, cultured in 
serum-free medium; Fig 9.4.1b, MCF-7 cells was serum-free 16 hours then treated with 200nM leptin for 6 
hours. 32P-Labeled cDNA probes generated from ploy (A)+ RNA isolated from MCF-7 cells were 
hybridized to a cDNA microarray containing 588 known human genes. The left upper box and left lower 
box encase those genes grouped as oncogenes/tumor suppressors/ cell cycle control proteins and DNA 
binding/ cell cycle control proteins / transcription factors, respectively. The results were shown from three 
independent experiments. The position of MAPK3 cDNA is indicated by ellipse and the relative expression 
level of cDNA is up-regulated. The position of vascular endothelial growth factor receptor 1 is also 
indicated by ellipse and the relative expression level of cDNA is down-regulated.  
         Up-regulated gene;     Down-regulated gene;  Housekeeping gene 
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Table 9.4.1  Identification by cDNA array of genes positively regulated by the human 
recombinant leptin in MCF-7 cells. 
Genes were considered positively regulated when they exhibited a 2-fold or greater increase in the presence 
of leptin compared to the absence of leptin. Fold regulation is calculated as the ratio of the level of gene 
expression in treated with leptin MCF-7 cells to that without leptin treated MCF-7 cells. 
 
Genebank 
Accession Fold stimulation Gene/Protein Name 
X05360 7.3 
Cell division control protein 2 homolog(CDC2); P34 protein kinase; 
Cyclin-dependent kinase (CDK1) 
M14505 2.00 
cell division protein kinase 4; Cyclin-dependent kinase 4(CDK4); 
PSK-J3 
L29222 2.58 CDC-like Kinase1 (CLK1) 
L29220 3.60 CDC-like Kinase3 (CLK3) 
L25676 2.06 
Cell division protein kinase 9(CDK9); serine/threonine protein kinase 
PITALRE 
U00001 2.85 CDC27HS protein 
L22005 2.24 
Ubiquitin -conjugating enzyme E2 32-kDa complementing protein; 
ubiquitin-protein ligase; ubiquitin carrier protein, CDC34 
U63131 2.70 CDC37 homolog 
X60188 2.31 
Mitogen-activated protein kinase 3 (MAP kinase 3; MAPK 3; PRKM3); 
extracelluar signal-regulated kinase1 (ERK1); ERT2 
L31951 2.2 
Mitogen-activated protein kinase 9 (MAPK 9; MAPk 9: PRKM9; 
c-jun N-terminal kinase 2 (JNK2) 
M29039 2.0 Jun-B 
M99061; 
S43636 4.38 




caspase 9 (CASP9); MCH6; ICE-like apoptotic protease 6 (ICE-LAP6); 
apoptotic proteases activating factor 3 (APAF3) 
M35543+M572
98 2.85 
CDC42 homolog; G25K GTP-binding protein (brain isoform+ placental 
isoform) 
U04045; 
L47583 2.19 DNA mismatch repair protein MSH-2 
J03250 4.15 DNA topoisomerase l (TOP1) 
X52773 2.03 Retinoid X receptor alpha (RXRA) 
X03168 2.20 Vitronectin (VTN); serum spreading factor; S-protein 
X94991; 
X95735 2.78 Zyxin 2(ZYX) 
D30751; 
M22490 2.06 Bone morphogenetic protein 4 (BMP4); BMP2B 
D13365; 
M93311 2.46 




Early growth response protein 1 (EGR1); transcription factor ETR 103; 
KROX24; zinc finger protein 225(ZNF 225); AT225 
X04602; 
M14584 2.57 
Interleukin 6 (IL6); B-cell stimulatory factor 2 (BSF2); interferon beta 2 
(IFNB2); hybridoma growth factor (HGF) 
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Table 9.4.2 Identification by cDNA array of genes negatively regulated by the human 
recombinant leptin in MCF-7 cells. 
Genes were considered negatively regulated when they exhibited a 2-fold or greater decrease in the presence 
of leptin compared to the absence of leptin treatment. Fold regulation is calculated as the ratio of the level of 





stimulation Gene/Protein Name 
L27211 0.37 
Cyclin-dependent kinase 4 inhibitor 2 (CDK41; CDKN2); P16-INK 4; 
multiple tumor suppressor 1 (MTS1) 
X80692 0.50 
Mitogen-activated protein kinase 6 (MAP kinase 6; MAPK 6; PRKM6); p97-
MAPK; extracelluar signal-regulated kinase3 (ERK3) 
U18671; 
M97934 0.46 113-kDa signal transducer and activator of transcription 2 (STAT2; STAT113) 
L07541 0.50 Replication factor C38-Kda subunit (RFC38); activator 1 38-Kda subunit  
M96684 0.37 
Purine-rich element-binding protein A (PURA); purine-rich single -stranded 
DNA-binding protein alpha (PUR-alpha) 
X91940 0.35 Wingless-related MMTV integration site 8b protein (WNT8B) 
M33294 0.22 
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A); tumor 
necrosis factor receptor 1(TNFR1); tumor necrosis factor alpha receptor 
(TNFAR); CD 120A antigen 
U72661 0.45 Ninjurin1 
U02687 0.30 
Stem cell tyrosine kinase 1 (STK1); FL cytokine receptor; tyrosine-protein 
kinase receptor flt3; CD 135 antigen 
X51602; 
U01134 0.44 
Vascular endothelial growth factor receptor 1 (VEGFR1); fms -related tyrosine 
kinase 1(FLT1); soluble VEGFR; soluble FLT (SFLT) 
X57766 0.50 Matrix metalloproteinase 11 (MMP11); stromelysin 3 
L20471 0.50 
basigin (BSG); leukocyte activation antigen M6; collagenase stimulatory 




Urokinase-type plasminogen activator receptor GPI-anchored form (U-PAR; 




L22080 0.32 Alpha 1 catenin (CTNNA1); cadherin-associated protein; alpha E-catenin 
U36223 0.42 
Fibroblast growth factor 8 (FGF8); androgen-induced growth factor (AIGF); 
HBGF8 
M57627 0.18 Interleukin 10(IL10); cytokine synthesis inhibitory factor (CSIF) 
A03911 0.29 Glia-derived neurite-promoting factor (GDNPG) 
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Chapter 10 Discussion and Conclusion 
 
The present preliminary study demonstrates that human leptin receptor mRNA and protein 
was expressed in the human breast cancer cell line MCF-7. The results also indicated that 
the role of leptin on mammary carcinoma cell line proliferation was mediated by the 
specific leptin receptor in vitro. In addition, cDNA microarray was used to investigate 
other leptin effects on the MCFR-7 breast cancer cell line. 
 
Previous demonstration of leptin stimulation of the P42/44 MAPK pathway [Baumann, et 
al, 1996; Bjørbæk, et al, 1997] has been documented. The pathway has been demonstrated 
to mediate mitogenesis and /or cellular transformation in response to various cellular 
stimuli. We have demonstrated that Phosphorylation Elk-1 (the p44/42 MAP kinase 
dependent transcription factor) mediated transcription was enhanced by recombinant 
leptin stimulation. The present experiments also demonstrated that the addition of human 
recombinant leptin stimulated MAP kinase actively in dose and time dependent manner, 
accompanied by an increase in the proliferation of MCF-7 cells. The results obtained for 
BrdU incorporation showed that DNA synthesis was altered in MCF-7 cells stimulated by 
leptin. The BrdU assay shows the number of living cells and therefore the results obtained 
for BrdU uptake may more directly reflect cell proliferation activity and this may explain 
the difference in the dose-related effect of leptin on MCF-7 cell proliferation. 
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The present study also demonstrated that leptin stimulated cell proliferation could be 
completely inhibited with the inhibitor for MEK1/2 (U0126). Particularly, the fact that the 
addition of U0126 before treatment with leptin also prevented the human recombinant 
leptin induced increase in cell proliferation indicating the involvement of MAP kinase in 
MCF-7 cell proliferation. Leptin has been reported to utilize Elk-1 to mediate lept in-
induced transcription of egr-1 [Brann et al, 2002], which may provide a possible 
mechanism for the p44/42 MAP kinase dependent component of leptin-stimulated 
proliferation. 
 
In cDNA microarray analysis, we have observed the specific increases and decreases in 
the levels of mRNA expression of MCF-7 cells by leptin stimulation. We have  
demonstrated that not only Mitogen-activated protein kinases were up regulated in 
response to leptin, but also Type II cytoskeletal 2 epidermal keratin (KRT2E), Interleukin 
6 (IL6); and many cell division genes were up regulated also. While Cyclin-dependent 
kinase 4 inhibitor 2 (CDK41; CDKN2) Interleukin 10(IL10); cytokine synthesis inhibitory 
factor (CSIF); Glia-derived neurite-promoting factor (GDNPG) were down regulated, 
which is consistent with some previous reports [Tartaglia, et al, 1995; Baumann, et al, 
1996; White, et al, 1997]. 
 
Indeed, leptin has been reported to activate the proliferation of pancreatic-ß cells [Islam,et 
al, 1997], vascular endothelial cells [Sierra-honigmann, et al, 1998], lung cells [Tsuchiya, 
et al,1999], gastric mucosa cells [Schneider, et al, 2001], keratinocytes [Stallmeyer, et al, 
2001], and preadipose cells [Machinal-Quelin, et al, 2002]. Moreover, higher serum leptin 
levels are present in obese women who have a higher risk of breast cancer compared to 
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normal weight women. Thus besides other factors, leptin could be a possible additional 
factor contributing to mammary epithelium hyperplasia.  
 
A lot of evidence has suggested that the local cellular environment and particularly the 
mammary adipose cells play an integral role in controlling the proliferation of both normal 
and neoplastic mammary epithelial cells. Mammary adipose tissue is an important source 
of paracrine mitogens or anti-mitogens including, insulin-like growth factor 1 (IGF1), 
transforming growth factor a (TGFa), estrogens, and cytokines (TNFa, IL6). Leptin is 
another cytokine, mainly produced by adipose tissue and thus may also be relevant. 
 
The preliminary studies of leptin in the mammary carcinoma cell MCF-7 in vitro 
presented here permit the following conclusions: 
 
The human leptin receptor (OB-Rb) exists in the human breast cancer cell line MCF-7. 
Human recombinant leptin stimulated MCF-7 cell proliferation by increasing the activity 
of cell proliferation-related enzymes such as MAP kinase. From the cDNA microarray, it 
is possible that a number of the regulated genes may be of importance in mediating the 
effects of leptin proliferation on mammary carcinoma.  
 
This study also suggests that by acting as a proliferation factor on epithelial cell growth, 
leptin could play directly or indirectly an important role in normal and neoplastic 
mammary gland growth.  
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Further work will be necessary to delineate how these genes integrate the response of the 
cell to leptin. What also needs to be determined is the mechanism and sequential order by 
which these genes are regulated by leptin. 
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(Woman’s Health Research) 
 
 
Date of interview ££/ ££/ ££ 
   m       m       d      d         y    y  
 
Date of diagnosis ££/ ££/ ££ 
    m       m       d      d         y    y  
 
Nationality group £ 1 Chinese 
    2 Malay 




If you are not a Singapore resident, which year did you come to Singapore? 
   ££££ 
 
Country of birth  £ 1 Singapore  
2 Malaysia 
3 P R China 
    4 India  
5 Other_________ 
 
Date of birth  ££/ ££/ ££  
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Do you still have the regularity menstrual period? 
1=Yes (skip to next section) 
2=No 
 
If you have not regularity menstrual period, the 




££/ ££  
 m       m         y    y 
 
H3 How old were you when you had your first 
regular menstrual period? 
££  years old 
H4* How often are/were your menstrual periods? 
Record cycle length in days (e.g. once in 28 days) 
If less often than monthly, record approximate number of 
days (e.g. 60 for 2-monthly). 







Have you taken any medicine (oral contraceptive/ 
estrogen pill/ traditional Chinese medicine) that 
interrupted your menstrual cycling? 
1=no (skip to next section) 
2=yes 













Your marital status is 













££  years old 












How many children do you have? 




4=more than 3 children 
 
When was your First Full Term Pregnancy? 
 
If you gave your child/ children breast-feeding, 
the total months is_________ 
If you have 2 children, the breast-feeding time is the months 





££  years old 
 














Have you ever taken oral contraceptives / female 
hormone (pills/ implants)? 
1=never (skip to next section) 
2=ever 
 
If you have taken oral contraceptives/ female 
hormone (pills/implants), it is/was 
1=in regularity menstrual period 
2=in the period of menstruation ceasing (have not 
menstrual at least 6 months) 
3=in irregularity menstrual period 
 
If you have taken oral contraceptives/ female 
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*Pregnancy Year Outcome 





If the outcome is not 
full term baby, when 
did the termination of 
pregnancy occur? 
1 ___________ £ ____________months 
2 ___________ £ ____________months 
3 ___________ £ ____________months 
4 ___________ £ ____________months 
5 ___________ £ ____________months 
6 ___________ £ ____________months 
 Socioeconomic Status  Please fill in your answer 
S1 Your highest level of your educational 
qualifications is  









S2 Which kind of house do you live in? 
1=HDB/ JTC/ Other Government 1~3-room flat 
(include shophouse, attap/ Zinc-roofed dwelling) 
2=HDB 4-room flat 
3=HDB 5-room flat 
4=HDB executive flat 
5=Private apt or condominium 
6=Terrace/ semi-detached/ bungalow 
 
£ 
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Has anyone in your family ever had cancer? 
1=no (skip to next section) 
2=yes 
 
Was it your __________? 
1=Parent, sibling or child 
2=husband or husband’s family 
3=other relative _________ 
 
















Have you had a history of breast lump? 
1=no (skip to next section) 
2=yes 
 











When did you have the regular breast examination 
last time? 
 
Is there any abnormal on it? 
1=no 
2=yes (specify_________) 
££/ ££  






What is your height currently? 
 
What was your height at age 18? 
£££  cm 




What is your weight currently? 
 
What was your weight at age 18? 
££  kg 
££  kg 














Have you ever smoked a cigarette (or any other 
form of tobacco at least one a day for a year)? 
1=never (skip to next section) 
2=ever, hand rolled cigarette  
3=ever, manufactured cigarette 
4=ever, other form (specify___________) 
 
At what age did you start smoking? 
 
At what age did you stop smoking? 
 






££  years old 
 
££  years old 












Have you ever taken alcohol (beer/wine/ brandy/ 
spirits/ liquor)? 
1=never (skip to next section) 
2=ever 
 
At what age did you start drinking alcohol? 
 
At what age did you stop drinking alcohol? 
 
On average, how many glasses/shots did you 




££  years old 
 
££  years old 
 
££  glasses/shots per 
week/month 
Note: *  For interview 
In case we need to clarify some of this information with you could I have your contact 
number?       £££££££ 
Thank you for your help! 
 




I, __________________________agree to participate in this research project conducted 
by the National University of Singapore on Woman’s health research. I understand that I 
am asked to provide information about matters concerning myself and my health, and that 
the doctors involved in this study may require further information from my medical 
records. I also understand that all this information will be kept confidential and available 
only to the doctors involved in the study. 
 
 
Signed:_________________________ Witnessed by___________________ 
Date:___________________________   __________________ 
        (Name of witness) 
 
 
 
 
